| Year |
Citation |
Score |
| Low-probability matches (unlikely to be authored by this person) |
| 2023 |
Forget A, Adegboye C, Alfieri M, Yim R, Flaherty K, Mathur H, O'Connell AE. A sepsis trigger tool reduces time to antibiotic administration in the NICU. Journal of Perinatology : Official Journal of the California Perinatal Association. PMID 36813901 DOI: 10.1038/s41372-023-01636-1 |
0.01 |
|
| 2022 |
Laureano AS, Flaherty K, Hinman AM, Jadali A, Nakamura T, Higashijima SI, Sabaawy HE, Kwan KY. shox2 is required for vestibular statoacoustic neuron development. Biology Open. 11. PMID 36594417 DOI: 10.1242/bio.059599 |
0.01 |
|
| 2021 |
Yu S, Wei S, Savani M, Lin X, Du K, Mender I, Siteni S, Vasilopoulos T, Reitman ZJ, Ku Y, Wu D, Liu H, Tian M, Chen Y, Labrie M, ... ... Flaherty K, et al. A Modified Nucleoside 6-thio-2'-deoxyguanosine Exhibits Anti-tumor Activity in Gliomas. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34593527 DOI: 10.1158/1078-0432.CCR-21-0374 |
0.01 |
|
| 2021 |
Karam JA, Puligandla M, Flaherty KT, Uzzo RG, Matin SF, Pins MR, Wood CG, Kane C, Jewett MAS, Kim SE, Dutcher JP, DiPaola RS. Adjuvant therapy in patients with sarcomatoid RCC: Post hoc analysis from ECOG-ACRIN E2805. Bju International. PMID 34480522 DOI: 10.1111/bju.15587 |
0.01 |
|
| 2021 |
Bai X, Hu J, Betof Warner A, Quach HT, Cann CG, Zhang MZ, Si L, Tang B, Cui C, Yang X, Wei X, Pallan L, Harvey C, Manos MP, Ouyang O, ... ... Flaherty KT, et al. Early use of high-dose-glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34376536 DOI: 10.1158/1078-0432.CCR-21-1283 |
0.01 |
|
| 2021 |
Flaherty KT, Doroshow JH, Galbraith S, Ribas A, Kluetz PG, Pazdur R, Theoret MR. Rethinking Cancer Clinical Trial Conduct Induced by COVID-19: An Academic Center, Industry, Government, and Regulatory Agency Perspective. Cancer Discovery. 11: 1881-1885. PMID 34290074 DOI: 10.1158/2159-8290.CD-21-0850 |
0.01 |
|
| 2021 |
Schadendorf D, Robert C, Dummer R, Flaherty KT, Tawbi HA, Menzies AM, Banerjee H, Lau M, Long GV. Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers. European Journal of Cancer (Oxford, England : 1990). 153: 234-241. PMID 34225229 DOI: 10.1016/j.ejca.2021.05.005 |
0.01 |
|
| 2021 |
Schiferle EB, Cheon SY, Ham S, Son HG, Messerschmidt JL, Lawrence DP, Cohen JV, Flaherty KT, Moon JJ, Lian CG, Sullivan RJ, Demehri S. Rejection of benign melanocytic nevi by nevus-resident CD4 T cells. Science Advances. 7. PMID 34162549 DOI: 10.1126/sciadv.abg4498 |
0.01 |
|
| 2021 |
Brase JC, Walter RFH, Savchenko A, Gusenleitner D, Garrett J, Schimming TT, Váraljai R, Castelletti D, Kim JY, Dakappagari NK, Schultz K, Robert C, Long GV, Nathan PD, Ribas A, ... Flaherty KT, et al. Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 34108180 DOI: 10.1158/1078-0432.CCR-20-3586 |
0.01 |
|
| 2021 |
Jhaveri KL, Wang XV, Makker V, Luoh SW, Mitchell EP, Zwiebel JA, Sharon E, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, ... ... Flaherty KT, et al. Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830]. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 34099371 DOI: 10.1016/j.annonc.2021.05.797 |
0.01 |
|
| 2021 |
Gogas H, Dummer R, Ascierto PA, Arance A, Mandalà M, Liszkay G, Garbe C, Schadendorf D, Krajsová I, Gutzmer R, Sileni VC, Dutriaux C, Yamazaki N, Loquai C, Queirolo P, ... ... Flaherty KT, et al. Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS). European Journal of Cancer (Oxford, England : 1990). 152: 116-128. PMID 34091420 DOI: 10.1016/j.ejca.2021.04.028 |
0.01 |
|
| 2021 |
Liu D, Lin JR, Robitschek EJ, Kasumova GG, Heyde A, Shi A, Kraya A, Zhang G, Moll T, Frederick DT, Chen YA, Wang S, Schapiro D, Ho LL, Bi K, ... ... Flaherty KT, et al. Evolution of delayed resistance to immunotherapy in a melanoma responder. Nature Medicine. PMID 33941922 DOI: 10.1038/s41591-021-01331-8 |
0.01 |
|
| 2021 |
Nebhan CA, Johnson DB, Sullivan RJ, Amaria RN, Flaherty KT, Sosman JA, Davies MA. Efficacy and Safety of Trametinib in Non-V600 BRAF Mutant Melanoma: A Phase II Study. The Oncologist. PMID 33861486 DOI: 10.1002/onco.13795 |
0.01 |
|
| 2021 |
Xu W, Puligandla M, Halbert B, Haas NB, Flaherty KT, Uzzo RG, Dutcher JP, DiPaola RS, Sabbisetti V, Bhatt RS. Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33832947 DOI: 10.1158/1078-0432.CCR-21-0025 |
0.01 |
|
| 2021 |
Guhan SM, Shaughnessy M, Rajadurai A, Taylor M, Kumar R, Ji Z, Rashid S, Flaherty K, Tsao H. The molecular context of vulnerability for CDK9 suppression in triple wild-type melanoma. The Journal of Investigative Dermatology. PMID 33745909 DOI: 10.1016/j.jid.2020.12.035 |
0.01 |
|
| 2021 |
Correa AF, Jegede OA, Haas NB, Flaherty KT, Pins MR, Adeniran A, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Dutcher JP, DiPaola RS, Carducci MA, Uzzo RG. Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma. European Urology. PMID 33707112 DOI: 10.1016/j.eururo.2021.02.025 |
0.01 |
|
| 2021 |
Cleary JM, Wang VX, Heist RS, Kopetz S, Mitchell EP, Zweibel J, Kapner KS, Chen HX, Li S, Gray RJ, McShane LM, Rubinstein L, Patton D, Meric-Bernstam F, Dillmon MS, ... ... Flaherty KT, et al. Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase 2 NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33637626 DOI: 10.1158/1078-0432.CCR-21-0066 |
0.01 |
|
| 2021 |
Bai X, Kim M, Kasumova G, Si L, Tang B, Cui C, Yang X, Wei X, Cohen J, Lawrence D, Freedman C, Fadden R, Rubin K, Sharova T, Frederick D, ... Flaherty K, et al. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort. Journal For Immunotherapy of Cancer. 9. PMID 33632901 DOI: 10.1136/jitc-2020-002092 |
0.01 |
|
| 2021 |
Lo JA, Kawakubo M, Juneja VR, Su MY, Erlich TH, LaFleur MW, Kemeny LV, Rashid M, Malehmir M, Rabi SA, Raghavan R, Allouche J, Kasumova G, Frederick DT, Pauken KE, ... ... Flaherty KT, et al. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Science Translational Medicine. 13. PMID 33597266 DOI: 10.1126/scitranslmed.abd8636 |
0.01 |
|
| 2021 |
Syeda MM, Wiggins JM, Corless BC, Long GV, Flaherty KT, Schadendorf D, Nathan PD, Robert C, Ribas A, Davies MA, Grob JJ, Gasal E, Squires M, Marker M, Garrett J, et al. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study. The Lancet. Oncology. PMID 33587894 DOI: 10.1016/S1470-2045(20)30726-9 |
0.01 |
|
| 2021 |
Saqlain F, Shalhout SZ, Flaherty KT, Emerick KS, Miller DM. REDCap-Based Operational Tool to Guide Care Coordination in a Multidisciplinary Cutaneous Oncology Clinic. Jco Oncology Practice. OP2000673. PMID 33492980 DOI: 10.1200/OP.20.00673 |
0.01 |
|
| 2021 |
Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, et al. The State of Melanoma: Emergent Challenges and Opportunities. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33414132 DOI: 10.1158/1078-0432.CCR-20-4092 |
0.01 |
|
| 2021 |
Simeone E, Scognamiglio G, Capone M, Giannarelli D, Grimaldi AM, Mallardo D, Madonna G, Curvietto M, Esposito A, Sandomenico F, Sabbatino F, Bayless NL, Warren S, Ong S, Botti G, ... Flaherty KT, et al. A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation. Journal of Translational Medicine. 19: 17. PMID 33407577 DOI: 10.1186/s12967-020-02680-7 |
0.01 |
|
| 2021 |
Xu W, Puligandla M, Halbert B, Haas NB, Flaherty K, Uzzo RG, Dutcher JP, DiPaola RS, Sabbisetti V, Bhatt RS. Analysis of plasma KIM-1 as a biomarker for recurrence risk after resection for localized renal cell carcinoma. Journal of Clinical Oncology. 39: 342-342. DOI: 10.1200/JCO.2021.39.6_SUPPL.342 |
0.01 |
|
| 2021 |
Ascierto PA, Robert C, Nathan PD, Dummer R, Tawbi HA, Flaherty KT, Ribas A, Schadendorf D, Green S, Sandalic L, Lau MR, Romero T, Long GV. Pyrexia-related outcomes upon application of an adapted pyrexia management algorithm in patients (pts) with BRAF V600: Mutant unresectable or metastatic melanoma treated with dabrafenib plus trametinib (DabTram) in the COMBI-i trial. Journal of Clinical Oncology. 39: 9560-9560. DOI: 10.1200/JCO.2021.39.15_SUPPL.9560 |
0.01 |
|
| 2021 |
Dummer R, Flaherty K, Robert C, Arance AM, de Groot JW, Garbe C, Gogas H, Gutzmer R, Krajsová I, Liszkay G, Loquai C, Mandalà M, Schadendorf D, Yamazaki N, Pickard MD, et al. Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with BRAF V600-mutant melanoma. Journal of Clinical Oncology. 39: 9507-9507. DOI: 10.1200/JCO.2021.39.15_SUPPL.9507 |
0.01 |
|
| 2021 |
Jackman DM, Jegede O, Zauderer MG, Mitchell EP, Zwiebel J, Gray RJ, Li S, McShane L, Rubinstein L, Patton DR, Williams PM, Hamilton SR, Conley BA, Arteaga CL, Harris L, ... ... Flaherty K, et al. A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U. Journal of Clinical Oncology. 39: 3087-3087. DOI: 10.1200/JCO.2021.39.15_SUPPL.3087 |
0.01 |
|
| 2020 |
Kalinsky K, Hong F, McCourt CK, Sachdev JC, Mitchell EP, Zwiebel JA, Doyle LA, McShane LM, Li S, Gray RJ, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, ... ... Flaherty KT, et al. Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial. Jama Oncology. PMID 33377972 DOI: 10.1001/jamaoncol.2020.6741 |
0.01 |
|
| 2020 |
Gogas H, Dréno B, Larkin J, Demidov L, Stroyakovskiy D, Eroglu Z, Ferrucci PF, Pigozzo J, Rutkowski P, Mackiewicz J, Rooney I, Voulgari A, Troutman S, Pitcher B, Guo Y, ... ... Flaherty K, et al. Cobimetinib plus atezolizumab in BRAF wild-type melanoma: primary results from the randomized phase 3 IMspire170 study. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 33309774 DOI: 10.1016/j.annonc.2020.12.004 |
0.01 |
|
| 2020 |
Mueller KL, Theoret MR, Lemery SJ, Amiri-Kordestani L, Ariyan CE, Atkins MB, Berry DA, Blank CU, DeMichele A, Forde PM, Ibrahim N, Keegan P, Mitchell TC, Moss RA, Robert C, ... ... Flaherty K, et al. Neoadjuvant Therapy for Melanoma: A US Food and Drug Administration - Melanoma Research Alliance Public Workshop. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33188142 DOI: 10.1158/1078-0432.CCR-20-3285 |
0.01 |
|
| 2020 |
Shi A, Kasumova GG, Michaud WA, Cintolo-Gonzalez J, Díaz-Martínez M, Ohmura J, Mehta A, Chien I, Frederick DT, Cohen S, Plana D, Johnson D, Flaherty KT, Sullivan RJ, Kellis M, et al. Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome. Science Advances. 6. PMID 33188016 DOI: 10.1126/sciadv.abb3461 |
0.01 |
|
| 2020 |
Chen A, Flaherty K, O'Dwyer PJ, Giantonio B, Marinucci DM, Lee JW, Railey E, Smith ML, White C, Conley B. Tumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial. Jco Precision Oncology. 4. PMID 33163848 DOI: 10.1200/PO.20.00217 |
0.01 |
|
| 2020 |
Ji Z, Njauw CN, Guhan S, Kumar R, Reddy B, Rajadurai A, Flaherty K, Tsao H. Loss of ACK1 Upregulates EGFR and Mediates Resistance to BRAF inhibition. The Journal of Investigative Dermatology. PMID 33159968 DOI: 10.1016/j.jid.2020.06.041 |
0.01 |
|
| 2020 |
Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, Worrall D, Giguel F, Piechocka-Trocha A, Atyeo C, Fischinger S, Chan A, Flaherty KT, Hall K, Dougan M, et al. SARS-CoV-2 viral load is associated with increased disease severity and mortality. Nature Communications. 11: 5493. PMID 33127906 DOI: 10.1038/s41467-020-19057-5 |
0.01 |
|
| 2020 |
Flaherty KT, Gray RJ, Chen AP, Li S, McShane LM, Patton D, Hamilton SR, Williams PM, Iafrate AJ, Sklar J, Mitchell EP, Harris LN, Takebe N, Sims DJ, Coffey B, et al. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1903010. PMID 33048619 DOI: 10.1200/JCO.19.03010 |
0.01 |
|
| 2020 |
Flaherty KT, Hodi FS, Fisher DE. Author Correction: From genes to drugs: targeted strategies for melanoma. Nature Reviews. Cancer. PMID 33046838 DOI: 10.1038/s41568-020-00311-3 |
0.01 |
|
| 2020 |
Dummer R, Lebbé C, Atkinson V, Mandalà M, Nathan PD, Arance A, Richtig E, Yamazaki N, Robert C, Schadendorf D, Tawbi HA, Ascierto PA, Ribas A, Flaherty KT, Pakhle N, et al. Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i. Nature Medicine. PMID 33020648 DOI: 10.1038/s41591-020-1082-2 |
0.01 |
|
| 2020 |
O'Shea A, Tam AL, Kilcoyne A, Flaherty KT, Lee SI. Image-guided biopsy in the age of personalised medicine: strategies for success and safety. Clinical Radiology. PMID 32896425 DOI: 10.1016/j.crad.2020.08.010 |
0.01 |
|
| 2020 |
Marusak C, Thakur V, Li Y, Freitas JT, Zmina P, Chang M, Gao M, Tan J, Xiao M, Lu Y, Mills GB, Flaherty K, Frederick DT, Miao B, Sullivan RJ, et al. Targeting Extracellular Matrix Remodeling restores BRAF Inhibitor Sensitivity in BRAFi Resistant Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32820016 DOI: 10.1158/1078-0432.Ccr-19-2773 |
0.01 |
|
| 2020 |
Boshuizen J, Vredevoogd DW, Krijgsman O, Ligtenberg MA, Blankenstein S, de Bruijn B, Frederick DT, Kenski JCN, Parren M, Brüggemann M, Madu MF, Rozeman EA, Song JY, Horlings HM, Blank CU, ... ... Flaherty KT, et al. Reversal of pre-existing NGFR-driven tumor and immune therapy resistance. Nature Communications. 11: 3946. PMID 32770055 DOI: 10.1038/s41467-020-17739-8 |
0.01 |
|
| 2020 |
Salama AKS, Li S, Macrae ER, Park JI, Mitchell EP, Zwiebel JA, Chen HX, Gray RJ, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Armstrong DK, Conley BA, ... ... Flaherty KT, et al. Dabrafenib and Trametinib in Patients With Tumors With Mutations: Results of the NCI-MATCH Trial Subprotocol H. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2000762. PMID 32758030 DOI: 10.1200/Jco.20.00762 |
0.01 |
|
| 2020 |
Ascierto PA, Ribas A, Larkin J, McArthur GA, Lewis KD, Hauschild A, Flaherty KT, McKenna E, Zhu Q, Mun Y, Dréno B. Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials. Journal of Translational Medicine. 18: 294. PMID 32746839 DOI: 10.1186/s12967-020-02458-x |
0.01 |
|
| 2020 |
Bai X, Flaherty KT. Targeted and immunotherapies in BRAF mutant melanoma - where we are standing and what to expect. The British Journal of Dermatology. PMID 32652567 DOI: 10.1111/bjd.19394 |
0.01 |
|
| 2020 |
Lazar I, Fabre B, Feng Y, Khateb A, Turko P, Martinez-Gomez MJ, Frederick DT, Levesque MP, Feld L, Zhang G, Zhang T, James B, Shklover J, Avitan Hersh E, Livneh I, ... ... Flaherty K, et al. SPANX control of Lamin A/C modulates nuclear architecture and promotes melanoma growth. Molecular Cancer Research : McR. PMID 32571981 DOI: 10.1158/1541-7786.Mcr-20-0291 |
0.01 |
|
| 2020 |
Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Arnon L, Zimmer L, Gutzmer R, Satzger I, Loquai C, Grabbe S, Vokes N, Margolis CA, Conway J, He MX, ... ... Flaherty K, et al. Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nature Medicine. PMID 32561875 DOI: 10.1038/S41591-020-0975-4 |
0.01 |
|
| 2020 |
Alicea GM, Rebecca VW, Goldman AR, Fane ME, Douglass SM, Behera R, Webster MR, Kugel CH, Ecker BL, Caino MC, Kossenkov AV, Tang HY, Frederick DT, Flaherty KT, Xu X, et al. Changes in Aged Fibroblast Lipid Metabolism Induce Age-dependent Melanoma Cell Resistance to Targeted Therapy Via the Fatty Acid Transporter FATP2. Cancer Discovery. PMID 32499221 DOI: 10.1158/2159-8290.Cd-20-0329 |
0.01 |
|
| 2020 |
Chae YK, Hong F, Vaklavas C, Cheng HH, Hammerman P, Mitchell EP, Zwiebel JA, Ivy SP, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, ... ... Flaherty KT, et al. Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902630. PMID 32463741 DOI: 10.1200/Jco.19.02630 |
0.01 |
|
| 2020 |
Enny A, Flaherty K, Mori S, Turner N, Nakamura T. Developmental Constraints on Fin Diversity. Development, Growth & Differentiation. PMID 32396685 DOI: 10.1111/dgd.12670 |
0.01 |
|
| 2020 |
O'Reilly EM, Barone D, Mahalingam D, Bekaii-Saab T, Shao SH, Wolf J, Rosano M, Krause S, Richards DA, Yu KH, Roach JM, Flaherty KT, Ryan DP. Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma. European Journal of Cancer (Oxford, England : 1990). 132: 112-121. PMID 32361265 DOI: 10.1016/j.ejca.2020.03.005 |
0.01 |
|
| 2020 |
Mardis ER, Ribas A, Hait WN, Jaffee EM, Foti M, Abate-Shen C, Albini A, Bernards R, Cruz-Correa MR, Flaherty KT, Greenberg PD, June CH, Knudsen KE, Liu ET, Mills GB, et al. AACR calls on congress to take immediate action against COVID-19 and protect patients with cancer during the pandemic Cancer Discovery. 10: 771-774. PMID 32295764 DOI: 10.1158/2159-8290.Cd-20-0449 |
0.01 |
|
| 2020 |
Ugurel S, Röhmel J, Ascierto PA, Becker JC, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Livingstone E, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Zimmer L, et al. Survival of patients with advanced metastatic melanoma: The impact of MAP kinase pathway inhibition and immune checkpoint inhibition - Update 2019. European Journal of Cancer (Oxford, England : 1990). 130: 126-138. PMID 32179447 DOI: 10.1016/j.ejca.2020.02.021 |
0.01 |
|
| 2020 |
Dummer R, Brase JC, Garrett J, Campbell CD, Gasal E, Squires M, Gusenleitner D, Santinami M, Atkinson V, Mandalà M, Chiarion-Sileni V, Flaherty K, Larkin J, Robert C, Kefford R, et al. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. The Lancet. Oncology. PMID 32007138 DOI: 10.1016/S1470-2045(20)30062-0 |
0.01 |
|
| 2020 |
Johnson DB, Zhao F, Noel MS, Riely GJ, Mitchell EP, Wright JJ, Chen HX, Gray RJ, Li S, McShane LM, Rubinstein L, Patton D, Williams M, Hamilton SR, Conley BA, ... ... Flaherty KT, et al. Trametinib activity in patients with solid tumors and lymphomas harboring BRAF non-V600 mutations or fusions: results from NCI-MATCH (EAY131). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31924734 DOI: 10.1158/1078-0432.Ccr-19-3443 |
0.01 |
|
| 2020 |
Flaherty KT, Gray R, Chen A, Li S, Patton D, Hamilton SR, Williams PM, Mitchell EP, Iafrate AJ, Sklar J, Harris LN, McShane LM, Rubinstein LV, Sims DJ, Routbort M, et al. THE MOLECULAR ANALYSIS FOR THERAPY CHOICE (NCI-MATCH) TRIAL: LESSONS for GENOMIC TRIAL DESIGN. Journal of the National Cancer Institute. PMID 31922567 DOI: 10.1093/Jnci/Djz245 |
0.01 |
|
| 2020 |
Ascierto PA, Dummer R, Gogas HJ, Flaherty KT, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, de Groot JWB, Loquai C, Gollerkeri A, Pickard MD, et al. Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. European Journal of Cancer (Oxford, England : 1990). 126: 33-44. PMID 31901705 DOI: 10.1016/j.ejca.2019.11.016 |
0.01 |
|
| 2020 |
Robert C, Grob J, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Sileni V, Schachter J, Garbe C, Bondarenko I, Nathan P, Ribas A, Davies M, Flaherty K, Burgess P, et al. Characteristics of Patients With a Complete Response Treated With Dabrafenib + Trametinib Combination Therapy: Findings From Pooled COMBI-d and COMBI-v 5-Year Analysis Skin the Journal of Cutaneous Medicine. 4: s112. DOI: 10.25251/skin.4.supp.112 |
0.01 |
|
| 2020 |
Cleary JM, Iyer G, Oh D, Mellinghoff IK, Goyal L, Ng MC, Meric-Bernstam F, Matos I, Chao T, Ait Sarkouh R, Cretegny K, Nicolas-Metral V, Pokorska-Bocci A, Vaslin A, Zanna C, ... ... Flaherty K, et al. Final results from the phase I study expansion cohort of the selective FGFR inhibitor Debio 1,347 in patients with solid tumors harboring an FGFR gene fusion. Journal of Clinical Oncology. 38: 3603-3603. DOI: 10.1200/jco.2020.38.15_suppl.3603 |
0.01 |
|
| 2020 |
Damodaran S, Zhao F, Deming DA, Mitchell EP, Wright JJ, Doyle LA, Gray RJ, Li S, McShane L, Rubinstein LV, Patton DR, Williams M, Hamilton SR, Suga JM, Conley BA, ... ... Flaherty K, et al. Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F. Journal of Clinical Oncology. 38: 3506-3506. DOI: 10.1200/Jco.2020.38.15_Suppl.3506 |
0.01 |
|
| 2020 |
Blum SM, Smith N, Sade-Feldman M, Frederick DT, Jenkins RW, Cohen JV, Lawrence DP, Mooradian M, Freedman C, Fadden R, Rubin KM, Richey S, Flaherty K, Wargo JA, Hacohen N, et al. Investigating the tumor immune infiltrate for populations that predict immune-related adverse events (irAEs) in patients receiving PD-1 inhibitors. Journal of Clinical Oncology. 38: 3116-3116. DOI: 10.1200/Jco.2020.38.15_Suppl.3116 |
0.01 |
|
| 2020 |
Bradbury AR, Lee J, Gaieski JB, Li S, Gareen IF, Flaherty K, Herman BA, DeMichele A, Domchek SM, Maxwell KN, Onitilo AA, Virani S, Park S, Faller BA, Grant SC, et al. Randomized trial of web-based genetic education versus usual care in advanced cancer patients undergoing tumor genetic testing: Results from the ECOG-ACRIN NCI Community Oncology Research Program (NCORP; EAQ152) COMET trial. Journal of Clinical Oncology. 38: 2008-2008. DOI: 10.1200/Jco.2020.38.15_Suppl.2008 |
0.01 |
|
| 2020 |
Mehta A, Rucevic M, Sprecher E, Rosenberg LH, Lieb D, Kasumova GG, Kim MS, Bai X, Frederick DT, Flaherty K, Sullivan RJ, Hacohen N, Boland GM. The use of plasma proteomic markers to understand the biology of immunotherapy response. Journal of Clinical Oncology. 38: 10062-10062. DOI: 10.1200/Jco.2020.38.15_Suppl.10062 |
0.01 |
|
| 2020 |
Dummer R, Biette K, Gusenleitner D, Ramesh R, Lebbe C, Atkinson V, Mandalà M, Nathan PD, Arance A, Richtig E, Yamazaki N, Robert C, Schadendorf D, Tawbi HA, Ascierto PA, ... ... Flaherty K, et al. Effect of first-line spartalizumab + dabrafenib + trametinib on immunosuppressive features detected in peripheral blood and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma. Journal of Clinical Oncology. 38: 10034-10034. DOI: 10.1200/jco.2020.38.15_suppl.10034 |
0.01 |
|
| 2020 |
Long GV, Lebbe C, Atkinson V, Mandalà M, Nathan PD, Arance A, Richtig E, Yamazaki N, Robert C, Schadendorf D, Tawbi HA, Ascierto PA, Ribas A, Flaherty K, Pakhle N, et al. The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial. Journal of Clinical Oncology. 38: 10028-10028. DOI: 10.1200/jco.2020.38.15_suppl.10028 |
0.01 |
|
| 2020 |
Gogas H, Ascierto PA, Flaherty K, Arance A, Mandalà M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, de Groot JW, Dutriaux C, Loquai C, Gollerkeri A, Pickard MD, et al. Update on overall survival in COLUMBUS: A randomized phase III trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in patients with BRAF V600-mutant melanoma. Journal of Clinical Oncology. 38: 10012-10012. DOI: 10.1200/JCO.2020.38.15_SUPPL.10012 |
0.01 |
|
| 2020 |
Mehta A, Rucevic M, Sprecher E, Rosenberg LH, Lieb D, Kasumova G, Kim MS, Bai X, Frederick DT, Flaherty K, Sullivan RJ, Hacohen N, Boland G. Abstract LB-260: The use of blood-based protein biomarkers to uncover determinants of immunotherapy response in melanoma Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Lb-260 |
0.01 |
|
| 2020 |
Cleary JM, Wang V, Heist R, Kopetz S, Mitchell EP, Zwiebel J, Chen HX, Li S, Gray R, McShane L, Rubinstein L, Patton D, Meric-Bernstam F, Dillmon M, Williams M, ... ... Flaherty K, et al. Abstract CT061: Binimetinib in patients with tumors with NRAS mutations: NCI-MATCH ECOG-ACRIN Cancer Research Group subprotocol EAY131-Z1A Cancer Research. 80. DOI: 10.1158/1538-7445.Am2020-Ct061 |
0.01 |
|
| 2020 |
Freeman SS, Sade-Feldman M, Kim J, Stewart C, Ravi A, Arniella M, Yizhak K, Leshchiner I, Elagina L, Spiro O, Livitz D, Rosebrock D, Aguet F, Carrot-Zhang J, Gonye A, ... ... Flaherty KT, et al. Abstract 6670: Combined signals from tumor and immune cells predict outcomes of checkpoint inhibition in melanoma Immunology. 80: 6670-6670. DOI: 10.1158/1538-7445.Am2020-6670 |
0.01 |
|
| 2020 |
Bai X, Kim M, Kasumova G, Si L, Tang B, Cui C, Yang X, Wei X, Cohen J, Lawrence D, Freedman C, Fadden R, Rubin K, Sharova T, Frederick D, ... Flaherty K, et al. 228 Radiological dynamics and resistance types in patients with advanced melanoma treated with anti-PD-1 monotherapy Journal For Immunotherapy of Cancer. 8: A246-A246. DOI: 10.1136/jitc-2020-sitc2020.0228 |
0.01 |
|
| 2020 |
Boland GM, Flaherty KT. Tracking early response to immunotherapy Nature Cancer. 1: 160-162. DOI: 10.1038/s43018-020-0032-8 |
0.01 |
|
| 2020 |
Mandala M, Arance A, Dummer R, Ascierto P, Gogas H, Liszkay G, Garbe C, Schadendorf D, Krajsová I, Gutzmer R, Chiarion Sileni V, Dutriaux C, Loquai C, Tadmouri A, Pickard M, ... ... Flaherty K, et al. PCN40 Healthcare Resource Utilization in Patients Treated with Encorafenib PLUS Binimetinib for BRAF-Mutant Metastatic Melanoma: DATA from Columbus, a Phase 3 Trial in BRAF-Mutant Melanoma Value in Health. 23: S428. DOI: 10.1016/j.jval.2020.08.177 |
0.01 |
|
| 2020 |
Connolly R, Wang V, Hyman D, Grivas P, Mitchell E, Wright J, Sharon E, Gray R, Li S, McShane L, Rubinstein L, Patton D, Williams P, Hamilton S, Conley B, ... ... Flaherty K, et al. 553P Activity of trastuzumab and pertuzumab (HP) in patients with non-breast/gastroesophgeal HER2-amplified tumours: Results of the NCI-MATCH trial (EAY131) subprotocol J Annals of Oncology. 31: S479-S480. DOI: 10.1016/j.annonc.2020.08.667 |
0.01 |
|
| 2020 |
Nathan P, Dummer R, Long G, Ascierto P, Tawbi H, Robert C, Rutkowski P, Leonov O, Dutriaux C, Mandala' M, Lorigan P, Ferrucci P, Flaherty K, Brase J, Green S, et al. LBA43 Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial Annals of Oncology. 31: S1172. DOI: 10.1016/j.annonc.2020.08.2273 |
0.01 |
|
| 2020 |
Robert C, Flaherty K, Gogas H, Fernandez AA, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, de Groot J, Dutriaux C, Loquai C, Harney A, Kiprilov E, et al. 1127P Correlation of BRAF mutation status in circulating tumour DNA (ctDNA) with tumour biopsy and clinical outcomes in COLUMBUS Annals of Oncology. 31: S757-S758. DOI: 10.1016/j.annonc.2020.08.1250 |
0.01 |
|
| 2019 |
Matos I, Goyal L, Cleary J, Voss M, Oh D, Bernstam FM, Ng C, Iyer G, Ishii N, Hu Y, Chessex AV, Pokorska-Bocci A, Nicolas V, Kirpicheva Y, Zanna C, ... Flaherty K, et al. Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 30: iv122-iv123. PMID 32085006 DOI: 10.1093/annonc/mdz157.002 |
0.01 |
|
| 2019 |
Liu D, Schilling B, Liu D, Sucker A, Livingstone E, Jerby-Amon L, Zimmer L, Gutzmer R, Satzger I, Loquai C, Grabbe S, Vokes N, Margolis CA, Conway J, He MX, ... ... Flaherty K, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nature Medicine. PMID 31792460 DOI: 10.1038/S41591-019-0654-5 |
0.01 |
|
| 2019 |
Azad NS, Gray RJ, Overman MJ, Schoenfeld JD, Mitchell EP, Zwiebel JA, Sharon E, Streicher H, Li S, McShane LM, Rubinstein L, Patton DR, Williams PM, Coffey B, Hamilton SR, ... ... Flaherty KT, et al. Nivolumab Is Effective in Mismatch Repair-Deficient Noncolorectal Cancers: Results From Arm Z1D-A Subprotocol of the NCI-MATCH (EAY131) Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900818. PMID 31765263 DOI: 10.1200/Jco.19.00818 |
0.01 |
|
| 2019 |
Montero J, Gstalder C, Kim DJ, Sadowicz D, Miles W, Manos M, Cidado JR, Paul Secrist J, Tron AE, Flaherty K, Stephen Hodi F, Yoon CH, Letai A, Fisher DE, Haq R. Destabilization of NOXA mRNA as a common resistance mechanism to targeted therapies. Nature Communications. 10: 5157. PMID 31727958 DOI: 10.1038/S41467-019-12477-Y |
0.01 |
|
| 2019 |
Turner N, Mikalauskaite D, Barone K, Flaherty K, Senevirathne G, Adachi N, Shubin NH, Nakamura T. The evolutionary origins and diversity of the neuromuscular system of paired appendages in batoids. Proceedings. Biological Sciences. 286: 20191571. PMID 31662089 DOI: 10.1098/Rspb.2019.1571 |
0.01 |
|
| 2019 |
Sullivan RJ, Hollebecque A, Flaherty KT, Shapiro GI, Rodon Ahnert J, Millward MJ, Zhang W, Gao L, Sykes A, Willard MD, Yu D, Schade AE, Crowe KJ, Flynn DL, Kaufman MD, et al. A Phase 1 Study of LY3009120, a Pan-RAF Inhibitor, in Patients with Advanced or Metastatic Cancer. Molecular Cancer Therapeutics. PMID 31645440 DOI: 10.1158/1535-7163.Mct-19-0681 |
0.01 |
|
| 2019 |
Lee Z, Jegede OA, Haas NB, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Flaherty KT, Dutcher JP, DiPaola RS, Uzzo RG. Local Recurrence Following Resection of Intermediate-High Risk Non-metastatic Renal Cell Carcinoma: An Anatomic Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. The Journal of Urology. 101097JU000000000000. PMID 31596672 DOI: 10.1097/Ju.0000000000000588 |
0.01 |
|
| 2019 |
Verma V, Shrimali RK, Ahmad S, Dai W, Wang H, Lu S, Nandre R, Gaur P, Lopez J, Sade-Feldman M, Yizhak K, Bjorgaard SL, Flaherty KT, Wargo JA, Boland GM, et al. Author Correction: PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1CD38 cells and anti-PD-1 resistance. Nature Immunology. PMID 31551574 DOI: 10.1038/S41590-019-0519-6 |
0.01 |
|
| 2019 |
Shaughnessy M, Lamuraglia G, Klebanov N, Ji Z, Rajadurai A, Kumar R, Flaherty K, Tsao H. Selective uveal melanoma inhibition with calcium channel blockade. International Journal of Oncology. PMID 31545410 DOI: 10.3892/ijo.2019.4873 |
0.01 |
|
| 2019 |
Wang VE, Xue JY, Frederick DT, Cao Y, Lin E, Wilson C, Urisman A, Carbone DP, Bernards R, Lito P, Settleman J, McCormick F, Flaherty KT. Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors Through Autocrine FGFR Pathway Activation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31515463 DOI: 10.1158/1078-0432.Ccr-18-2779 |
0.01 |
|
| 2019 |
Jhaveri KL, Wang XV, Makker V, Luoh SW, Mitchell EP, Zwiebel JA, Sharon E, Gray RJ, Li S, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Conley BA, ... ... Flaherty KT, et al. Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Sub-protocol Q. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 31504139 DOI: 10.1093/Annonc/Mdz291 |
0.01 |
|
| 2019 |
Xu W, Puligandla M, Manola J, Bullock AJ, Tamasauskas D, McDermott DF, Atkins MB, Haas NB, Flaherty K, Uzzo RG, Dutcher JP, DiPaola RS, Bhatt RS. Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31471309 DOI: 10.1158/1078-0432.CCR-19-0818 |
0.01 |
|
| 2019 |
Gogas HJ, Flaherty KT, Dummer R, Ascierto PA, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Sileni VC, Dutriaux C, de Groot JWB, Yamazaki N, et al. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management. European Journal of Cancer (Oxford, England : 1990). 119: 97-106. PMID 31437754 DOI: 10.1016/j.ejca.2019.07.016 |
0.01 |
|
| 2019 |
Lewis KD, Larkin J, Ribas A, Flaherty KT, McArthur GA, Ascierto PA, Dréno B, Yan Y, Wongchenko M, McKenna E, Zhu Q, Mun Y, Hauschild A. Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. British Journal of Cancer. PMID 31417188 DOI: 10.1038/s41416-019-0546-y |
0.01 |
|
| 2019 |
Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalá M, Millward M, Arance A, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 31406976 DOI: 10.1093/annonc/mdz221 |
0.01 |
|
| 2019 |
Sheng X, Yan X, Chi Z, Si L, Cui C, Tang B, Li S, Mao L, Lian B, Wang X, Bai X, Zhou L, Kong Y, Dai J, Wang K, ... ... Flaherty KT, et al. Axitinib in Combination With Toripalimab, a Humanized Immunoglobulin G Monoclonal Antibody Against Programmed Cell Death-1, in Patients With Metastatic Mucosal Melanoma: An Open-Label Phase IB Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900210. PMID 31403867 DOI: 10.1200/JCO.19.00210 |
0.01 |
|
| 2019 |
Aloia A, Müllhaupt D, Chabbert CD, Eberhart T, Flueckiger S, Vukolic A, Eichhoff OM, Irmisch A, Alexander LT, Scibona E, Frederick DT, Miao B, Tian T, Cheng C, Kwong LN, ... ... Flaherty KT, et al. A fatty acid oxidation-dependent metabolic shift regulates the adaptation of -mutated melanoma to MAPK inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31375515 DOI: 10.1158/1078-0432.Ccr-19-0253 |
0.01 |
|
| 2019 |
Kong Y, Yu J, Yan J, Guo Q, Chi Z, Tang B, Zheng B, Yu J, Yin T, Cheng Z, Wu X, Yu H, Dai J, Sheng X, Si L, ... ... Flaherty KT, et al. Genetic aberrations in the CDK4 pathway are associated with innate resistance to PD-1 blockade in Chinese patients with non-cutaneous melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31375512 DOI: 10.1158/1078-0432.Ccr-19-0475 |
0.01 |
|
| 2019 |
Verma V, Shrimali RK, Ahmad S, Dai W, Wang H, Lu S, Nandre R, Gaur P, Lopez J, Sade-Feldman M, Yizhak K, Bjorgaard SL, Flaherty KT, Wargo JA, Boland GM, et al. PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1CD38 cells and anti-PD-1 resistance. Nature Immunology. PMID 31358999 DOI: 10.1038/S41590-019-0441-Y |
0.01 |
|
| 2019 |
Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, Faries M, Fecher LA, Flaherty KT, Gershenwald JE, Hamid O, et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. The Lancet. Oncology. 20: e378-e389. PMID 31267972 DOI: 10.1016/S1470-2045(19)30332-8 |
0.01 |
|
| 2019 |
Correa AF, Jegede O, Haas NB, Flaherty KT, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MAS, Dutcher JP, DiPaola RS, Carducci MA, Uzzo RG. Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1900107. PMID 31216227 DOI: 10.1200/Jco.19.00107 |
0.01 |
|
| 2019 |
Lewis K, Hauschild A, Larkin J, Ribas A, Flaherty KT, McArthur GA, Dréno B, McKenna E, Zhu Q, Mun Y, Ascierto PA. Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib. European Journal of Cancer (Oxford, England : 1990). 116: 45-55. PMID 31173962 DOI: 10.1016/j.ejca.2019.05.002 |
0.01 |
|
| 2019 |
Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Gogas H, Mandalá M, Haanen JBAG, Lebbé C, Mackiewicz A, ... ... Flaherty KT, et al. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. The New England Journal of Medicine. PMID 31166680 DOI: 10.1056/NEJMoa1904059 |
0.01 |
|
| 2019 |
Bai X, Fisher DE, Flaherty KT. Cell-state dynamics and therapeutic resistance in melanoma from the perspective of MITF and IFNγ pathways. Nature Reviews. Clinical Oncology. PMID 30967646 DOI: 10.1038/s41571-019-0204-6 |
0.01 |
|
| 2019 |
Li Y, Tinoco R, Elmén L, Segota I, Xian Y, Fujita Y, Sahu A, Zarecki R, Marie K, Feng Y, Khateb A, Frederick DT, Ashkenazi SK, Kim H, Perez EG, ... ... Flaherty K, et al. Gut microbiota dependent anti-tumor immunity restricts melanoma growth in Rnf5 mice. Nature Communications. 10: 1492. PMID 30940817 DOI: 10.1038/S41467-019-09525-Y |
0.01 |
|
| 2019 |
Chat V, Ferguson R, Simpson D, Kazlow E, Lax R, Moran U, Pavlick A, Frederick D, Boland G, Sullivan R, Ribas A, Flaherty K, Osman I, Weber J, Kirchhoff T. Autoimmune genetic risk variants as germline biomarkers of response to melanoma immune-checkpoint inhibition. Cancer Immunology, Immunotherapy : Cii. PMID 30863922 DOI: 10.1007/s00262-019-02318-8 |
0.01 |
|
| 2019 |
Sahu AD, S Lee J, Wang Z, Zhang G, Iglesias-Bartolome R, Tian T, Wei Z, Miao B, Nair NU, Ponomarova O, Friedman AA, Amzallag A, Moll T, Kasumova G, Greninger P, ... ... Flaherty K, et al. Genome-wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy. Molecular Systems Biology. 15: e8323. PMID 30858180 DOI: 10.15252/Msb.20188323 |
0.01 |
|
| 2019 |
Alvarez-Breckenridge C, Giobbie-Hurder A, Gill CM, Bertalan M, Stocking J, Kaplan A, Nayyar N, Lawrence DP, Flaherty KT, Shih HA, Oh K, Batchelor TT, Cahill DP, Sullivan R, Brastianos P. Upfront Surgical Resection of Melanoma Brain Metastases Provides a Bridge Toward Immunotherapy-Mediated Systemic Control. The Oncologist. PMID 30796152 DOI: 10.1634/theoncologist.2018-0306 |
0.01 |
|
| 2019 |
Voss MH, Hierro C, Heist RS, Cleary JM, Meric-Bernstam F, Tabernero J, Janku F, Gandhi L, Iafrate AJ, Borger DR, Ishii N, Hu Y, Kirpicheva Y, Nicolas-Metral V, Pokorska-Bocci A, ... ... Flaherty KT, et al. A Phase I, Multicenter, Dose-Escalation Study of the Oral Selective FGFR inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30745300 DOI: 10.1158/1078-0432.Ccr-18-1959 |
0.01 |
|
| 2019 |
Maertens O, Kuzmickas R, Manchester HE, Emerson CE, Gavin AG, Guild CJ, Wong TC, De Raedt T, Bowman-Colin C, Hatchi E, Garraway LA, Flaherty KT, Pathania S, Elledge SJ, Cichowski K. MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability in BRAF, NRAS, and NF1 mutant melanomas. Cancer Discovery. PMID 30709805 DOI: 10.1158/2159-8290.Cd-18-0879 |
0.01 |
|
| 2019 |
Robert C, Flaherty K, Nathan P, Hersey P, Garbe C, Milhem M, Demidov L, Mohr P, Hassel JC, Rutkowski P, Dummer R, Utikal J, Kiecker F, Larkin J, D'Amelio A, et al. Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K-mutant advanced or metastatic melanoma. European Journal of Cancer (Oxford, England : 1990). 109: 61-69. PMID 30690294 DOI: 10.1016/j.ejca.2018.12.015 |
0.01 |
|
| 2019 |
Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, ... ... Flaherty KT, et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 176: 404. PMID 30633907 DOI: 10.1016/J.Cell.2018.12.034 |
0.01 |
|
| 2019 |
Tessmer MS, Flaherty KT. Harnessing Research Discoveries to Save Lives. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 23: 5325. PMID 28916616 DOI: 10.1158/1078-0432.CCR-17-2302 |
0.01 |
|
| 2019 |
Ng MCH, Goyal L, Bang Y, Oh D, Chao T, Cleary JM, Voss MH, Meric-Bernstam F, Iyer G, Heist RS, Ishii N, Kirpicheva Y, Pokorska-Bocci A, Vaslin A, Hu Y, ... ... Flaherty K, et al. AB065. P-36. Debio 1347 in patients with cholangiocarcinoma harboring an FGFR gene alteration: preliminary results Hepatobiliary Surgery and Nutrition. 8: AB065-AB065. DOI: 10.21037/HBSN.2019.AB065 |
0.01 |
|
| 2019 |
Bai X, Kim MS, Kasumova GG, Cohen JV, Lawrence DP, Freedman C, Fadden R, Rubin KM, Sharova T, Flaherty K, Sullivan RJ, Boland GM. Prognostic models for advanced melanoma patients treated with anti-PD-1 monotherapy. Journal of Clinical Oncology. 37: 133-133. DOI: 10.1200/JCO.2019.37.8_SUPPL.133 |
0.01 |
|
| 2019 |
Mehta A, Kasumova G, Rucevic M, Sallman-Almen M, Rosenberg LH, Kim MS, Lieb D, Bai X, Frederick DT, Sullivan RJ, Flaherty K, Hacohen N, Boland GM. Liquid biopsy using plasma proteomic profiling to reveal predictors of immunotherapy response. Journal of Clinical Oncology. 37: 130-130. DOI: 10.1200/Jco.2019.37.8_Suppl.130 |
0.01 |
|
| 2019 |
Xu W, Puligandla M, Haas NB, Flaherty K, Uzzo R, Dutcher JP, DiPaola RS, Bhatt RS. Angiogenic factor and cytokine analysis among patients with renal cell carcinoma treated with adjuvant VEGFR TKIs. Journal of Clinical Oncology. 37: 586-586. DOI: 10.1200/JCO.2019.37.7_SUPPL.586 |
0.01 |
|
| 2019 |
Hyman DM, Goyal L, Grivas P, Meric-Bernstam F, Tabernero J, Hu Y, Kirpicheva Y, Nicolas-Metral V, Pokorska-Bocci A, Vaslin A, Zanna C, Flaherty K. FUZE clinical trial: a phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of tumor histology. Journal of Clinical Oncology. 37: TPS3157-TPS3157. DOI: 10.1200/JCO.2019.37.15_SUPPL.TPS3157 |
0.01 |
|
| 2019 |
Bai X, Kim MS, Kasumova G, Cohen JV, Lawrence DP, Freedman C, Fadden R, Rubin KM, Sharova T, Frederick DT, Flaherty K, Sullivan RJ, Boland GM. Organ site-specific radiological responses in anti-PD-1 monotherapy treated advanced melanoma patients. Journal of Clinical Oncology. 37: 9552-9552. DOI: 10.1200/JCO.2019.37.15_SUPPL.9552 |
0.01 |
|
| 2019 |
Bai X, Kim MS, Kasumova G, Chen T, Cohen JV, Lawrence DP, Freedman C, Fadden R, Rubin KM, Sharova T, Frederick DT, Flaherty K, Sullivan RJ, Boland GM. Predictable early onset high-dose-glucocorticoid-associated-irAE and its predictive role in anti-PD-1 monotherapy treated advanced melanoma patients. Journal of Clinical Oncology. 37: 9544-9544. DOI: 10.1200/JCO.2019.37.15_SUPPL.9544 |
0.01 |
|
| 2019 |
Long GV, Lebbe C, Atkinson V, Mandalà M, Nathan PD, Arance Fernandez AM, Richtig E, Yamazaki N, Robert C, Schadendorf D, Tawbi HA, Ascierto PA, Ribas A, Flaherty K, Lee D, et al. The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-i. Journal of Clinical Oncology. 37: 9531-9531. DOI: 10.1200/JCO.2019.37.15_SUPPL.9531 |
0.01 |
|
| 2019 |
Dummer R, Gusenleitner D, Campbell CD, Lebbe C, Atkinson V, Mandalà M, Nathan PD, Arance A, Richtig E, Yamazaki N, Robert C, Schadendorf D, Tawbi HA, Ascierto PA, Ribas A, ... Flaherty K, et al. Tumor microenvironment (TME), longitudinal biomarker changes, and clinical outcome in patients (pts) with advanced BRAF V600–mutant melanoma treated with first-line spartalizumab (S) + dabrafenib (D) + trametinib (T). Journal of Clinical Oncology. 37: 9515-9515. DOI: 10.1200/JCO.2019.37.15_SUPPL.9515 |
0.01 |
|
| 2019 |
Syeda MM, WIGGINS JM, Corless B, Long GV, Flaherty K, Schadendorf D, Nathan PD, Robert C, Ribas A, Davies MA, Grob JJ, Gasal E, Squires M, Marker M, Brase JC, et al. Circulating tumor DNA (ctDNA) kinetics to predict survival in patients (pts) with unresectable or metastatic melanoma treated with dabrafenib (D) or D + trametinib (T). Journal of Clinical Oncology. 37: 9510-9510. DOI: 10.1200/JCO.2019.37.15_SUPPL.9510 |
0.01 |
|
| 2019 |
Nathan PD, Robert C, Grob JJ, Stroyakovskiy D, Karaszewska B, Hauschild A, Levchenko E, Chiarion Sileni V, Schachter J, Garbe C, Bondarenko I, Davies MA, Ribas A, Flaherty K, Burgess P, et al. Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma. Journal of Clinical Oncology. 37: 9507-9507. DOI: 10.1200/JCO.2019.37.15_SUPPL.9507 |
0.01 |
|
| 2019 |
Salama AK, Li S, Macrae ER, Park J, Mitchell EP, Zwiebel JA, Chen HX, Gray RJ, McShane L, Rubinstein L, Patton D, Williams PM, Hamilton SR, Armstrong DK, Conley BA, ... ... Flaherty K, et al. Dabrafenib and trametinib in patients with tumors with BRAF V600E/K mutations: Results from the molecular analysis for therapy choice (MATCH) Arm H. Journal of Clinical Oncology. 37: 3002-3002. DOI: 10.1200/Jco.2019.37.15_Suppl.3002 |
0.01 |
|
| 2019 |
Jerby L, Shah P, Cuoco MS, Rodman C, Su M, Melms JM, Leeson R, Kanodia A, Mei S, Lin J, Wang S, Rabasha B, Liu D, Zhang G, Margolais C, ... ... Flaherty K, et al. Abstract A082: Single-cell RNA-sequencing of metastatic melanoma identifies a cancer cell-intrinsic program associated with immune checkpoint inhibitor resistance Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A082 |
0.01 |
|
| 2019 |
Maertens O, Kuzmickas R, Manchester H, Emerson C, Gavin A, Guild C, Wong T, Raedt TD, Bowman-Colin C, Hatchi E, Garraway L, Flaherty K, Pathania S, Elledge S, Cichowski K. Abstract LB-113: MAPK pathway suppression unmasks latent DNA repair defects and confers a chemical synthetic vulnerability inBRAF,NRASandNF1-mutant melanomas Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Lb-113 |
0.01 |
|
| 2019 |
Clark AS, Hong F, Finn RS, DeMichele AM, Mitchell EP, Zweibel J, Arnaldez FI, McShane LM, Li S, Gray RJ, Rubenstein LV, Patton D, Williams PM, Hamilton SR, Copur MS, ... ... Flaherty KT, et al. Abstract LB-010: Molecular analysis for therapy choice (NCI-MATCH, EAY131) arm Z1B: Phase II trial of palbociclib forCCND1, 2 or 3amplified tumors Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-Lb-010 |
0.01 |
|
| 2019 |
Mehta A, Kasumova G, Shi A, Rucevic M, Sallman-Almen M, Rosenberg LH, Sprecher E, Ohmura J, Kim M, Lieb D, Bai X, Frederick DT, Kellis M, Sullivan RJ, Flaherty KT, et al. Abstract 4533: Plasma and exosome proteomic profiling for prediction of immunotherapy response and toxicity Cancer Research. 79: 4533-4533. DOI: 10.1158/1538-7445.Sabcs18-4533 |
0.01 |
|
| 2019 |
Bedard PL, Li S, Wisinski KB, Yang ES, Limaye SA, Mitchell EP, Zwiebel JA, Moscow J, Gray RJ, McShane LM, Rubenstein LV, Patton DR, Williams PM, Hamilton SR, Conley BA, ... ... Flaherty KT, et al. Abstract CT139: NCI Molecular Analysis for Therapy Choice (NCI-MATCH EAY131) arm B: Phase II study of afatinib in patients (pts) with HER2 (ERBB2) activating mutations Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct139 |
0.01 |
|
| 2019 |
Kummar S, Li S, Reiss K, Ford JM, Mitchell EP, Zwiebel JA, Takebe N, Gray RJ, McShane LM, Rubinstein LV, Patton D, Williams PM, Hamilton SR, Brufsky A, Conley BA, ... ... Flaherty KT, et al. Abstract CT138: NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containingBRCA1andBRCA2mutations Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct138 |
0.01 |
|
| 2019 |
Mehta A, Liu D, Shi A, Frederick DT, Ho L, Larque AB, Miao B, Raghavan RS, Sharova T, Shin JH, Rinaldi N, Chebib IA, Kellis M, Allen EV, Hacohen N, ... Flaherty KT, et al. Abstract 3013: Acquired resistance to immune checkpoint inhibition by melanoma phenotypic transformation Cancer Research. 79: 3013-3013. DOI: 10.1158/1538-7445.Am2019-3013 |
0.01 |
|
| 2019 |
Chen AP, Li S, Coffey B, Tricoli JV, Hamilton SR, Williams MP, Mitchell EP, Patton D, Gray RJ, McShane LM, Rubinstein LV, Arteaga CL, O'Dwyer PJ, Harris LN, Conley BA, ... Flaherty KT, et al. Abstract A089: Adolescent and young adult (AYA) cohort of the NCI MATCH clinical trial (EAY131) Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A089 |
0.01 |
|
| 2019 |
Harris LN, Gray RJ, Conley BA, Chen AP, Flaherty KT, Hamilton SR, Williams PM, Karlovich C, Patton D, Li S, McShane LM, Rubinstein LV, Mitchell EP, Tricoli JV, Little RF, et al. Abstract A079: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH): A successful precision medicine signal-seeking trial in patients (pts) with rare variants and refractory malignancies Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-A079 |
0.01 |
|
| 2019 |
Lee* Z, Jegede O, Haas NB, Pins MR, Messing EM, Manola J, Wood CG, Kane CJ, Jewett MA, Flaherty KT, Dutcher JP, DiPaola RS, Uzzo RG. MP14-18 AN ANATOMIC CLASSIFICATION SYSTEM FOR LOCAL RECURRENCE FOLLOWING RESECTION OF INTERMEDIATE AND HIGH RISK NON-METASTATIC RENAL CELL CARCINOMA: AN ANALYSIS OF THE ASSURE (ECOG-ACRIN 2805) TRIAL Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555314.30838.23 |
0.01 |
|
| 2019 |
Brastianos P, Cohen J, Wang N, Lee E, Ligibel J, Chukwueke U, Keeley M, Oh K, White M, Gerstner E, Batchelor T, Lawrence D, Ryan DP, Iafrate AJ, Giobbie-Hurder A, ... Flaherty K, et al. Cmet-33. Phase Ii Study Of Palbociclib In Brain Metastases Harboring Cdk Pathway Alterations Neuro-Oncology. 21. DOI: 10.1093/Neuonc/Noz175.234 |
0.01 |
|
| 2019 |
Arance A, Gogas H, Dreno B, Flaherty K, Demidov L, Stroyakovskiy D, Eroglu Z, Ferrucci P, Pigozzo J, Rutkowski P, Mackiewicz J, Rooney I, Voulgari A, Troutman S, Pitcher B, et al. Combination treatment with cobimetinib (C) and atezolizumab (A) vs pembrolizumab (P) in previously untreated patients (pts) with BRAFV600 wild type (wt) advanced melanoma: Primary analysis from the phase III IMspire170 trial Annals of Oncology. 30: v906. DOI: 10.1093/annonc/mdz394.066 |
0.01 |
|
| 2019 |
Davies M, Weber J, Flaherty K, McArthur G, Reddy M, Golden A, Culbertson J, Thomas C, Tawbi H, Long G. A phase II, open-label, randomized, multicenter trial of encorafenib + binimetinib evaluating a standard-dose and a high-dose regimen in patients with BRAFV600-mutant melanoma brain metastasis (MBM) (POLARIS) Annals of Oncology. 30: v562-v563. DOI: 10.1093/annonc/mdz255.067 |
0.01 |
|
| 2019 |
Robert C, Schadendorf D, Dummer R, Flaherty K, Tawbi H, Menzies A, D’Amelio A, de Jong E, Gasal E, Long G. Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials Annals of Oncology. 30: v545-v546. DOI: 10.1093/annonc/mdz255.026 |
0.01 |
|
| 2019 |
Grob J, Atkinson V, Robert C, Schadendorf D, Nathan P, Davies M, Kefford R, Dummer R, Kirkwood J, Flaherty K, Ribas A, Burgess P, Gasal E, Long G, Hauschild A. Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting Annals of Oncology. 30: v543-v544. DOI: 10.1093/annonc/mdz255.022 |
0.01 |
|
| 2019 |
Corcoran R, Do K, Cleary J, Parikh A, Yeku O, Weekes C, Veneris J, Ahronian L, Mauri G, Van Seventer E, Fetter I, Gurski J, Matulonis U, Juric D, Flaherty K, et al. Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours Annals of Oncology. 30: v164. DOI: 10.1093/Annonc/Mdz244.009 |
0.01 |
|
| 2019 |
Xu W, Puligandla M, Haas N, Flaherty K, Uzzo R, Sabbisetti V, Dutcher J, DiPaola R, Bhatt R. Plasma KIM-1 is associated with clinical outcomes after resection for localized renal cell carcinoma: A trial of the ECOG-ACRIN Research Group (E2805) Annals of Oncology. 30: v49. DOI: 10.1093/annonc/mdz239.066 |
0.01 |
|
| 2018 |
Janku F, Jegede O, Puhalla SL, Konstantinopoulos P, Meric-Bernstam F, Mitchell EP, Zwiebel JA, McShane LM, Li S, Rubinstein LV, Doyle LA, Patton D, Conley BA, O'Dwyer PJ, Harris LN, ... ... Flaherty KT, et al. NCI-MATCH Arms N & P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii137. PMID 32136211 DOI: 10.1093/Annonc/Mdy279.406 |
0.01 |
|
| 2018 |
Ojha R, Leli NM, Onorati A, Piao S, Verginadis II, Tameire F, Rebecca VW, Chude CI, Murugan S, Fennelly C, Noguera-Ortega E, Liu S, Xu X, Krepler C, Xiao M, ... ... Flaherty KT, et al. ER translocation of the MAPK pathway drives therapy resistance in BRAF mutant melanoma. Cancer Discovery. PMID 30563872 DOI: 10.1158/2159-8290.Cd-18-0348 |
0.01 |
|
| 2018 |
Lu H, Liu S, Zhang G, Wu B, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, ... ... Flaherty KT, et al. Author Correction: PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. PMID 30532003 DOI: 10.1038/S41586-018-0814-7 |
0.01 |
|
| 2018 |
Cohen JV, Flaherty KT. Response to immune checkpoint antibodies: Not all responses are created equal. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30510039 DOI: 10.1158/1078-0432.CCR-18-3296 |
0.01 |
|
| 2018 |
Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, Lieb DJ, Chen JH, Frederick DT, Barzily-Rokni M, Freeman SS, Reuben A, Hoover PJ, Villani AC, Ivanova E, ... ... Flaherty KT, et al. Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. Cell. 175: 998-1013.e20. PMID 30388456 DOI: 10.1016/J.Cell.2018.10.038 |
0.01 |
|
| 2018 |
Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ, Boland G, Flaherty K, Herlyn M, Ruppin E. Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nature Medicine. PMID 30333558 DOI: 10.1038/S41591-018-0247-8 |
0.01 |
|
| 2018 |
Smith MP, Rana S, Ferguson J, Rowling EJ, Flaherty KT, Wargo JA, Marais R, Wellbrock C. A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF /AXL melanoma. Pigment Cell & Melanoma Research. PMID 30277012 DOI: 10.1111/pcmr.12741 |
0.01 |
|
| 2018 |
Ascierto PA, Flaherty K, Goff S. Emerging Strategies in Systemic Therapy for the Treatment of Melanoma. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 38: 751-758. PMID 30231371 DOI: 10.1200/EDBK_199047 |
0.01 |
|
| 2018 |
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, ... ... Flaherty KT, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology. PMID 30219628 DOI: 10.1016/S1470-2045(18)30497-2 |
0.01 |
|
| 2018 |
Shah S, Luke JJ, Jacene HA, Chen T, Giobbie-Hurder A, Ibrahim N, Buchbinder EL, McDermott DF, Flaherty KT, Sullivan RJ, Lawrence DP, Ott PA, Hodi FS. Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma. Melanoma Research. PMID 30211813 DOI: 10.1097/CMR.0000000000000509 |
0.01 |
|
| 2018 |
Zheng J, Irani Z, Lawrence D, Flaherty K, Arellano RS. Combined Effects of Yttrium-90 Transarterial Radioembolization around Immunotherapy for Hepatic Metastases from Uveal Melanoma: A Preliminary Retrospective Case Series. Journal of Vascular and Interventional Radiology : Jvir. PMID 30174161 DOI: 10.1016/j.jvir.2018.04.030 |
0.01 |
|
| 2018 |
Auslander N, Zhang G, Lee JS, Frederick DT, Miao B, Moll T, Tian T, Wei Z, Madan S, Sullivan RJ, Boland G, Flaherty K, Herlyn M, Ruppin E. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nature Medicine. PMID 30127394 DOI: 10.1038/S41591-018-0157-9 |
0.01 |
|
| 2018 |
Hauschild A, Larkin J, Ribas A, Dréno B, Flaherty KT, Ascierto PA, Lewis KD, McKenna E, Zhu Q, Mun Y, McArthur GA. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials. Jama Oncology. PMID 30073321 DOI: 10.1001/jamaoncol.2018.2668 |
0.01 |
|
| 2018 |
Luoh SW, Flaherty KT. When Tissue Is No Longer the Issue: Tissue-Agnostic Cancer Therapy Comes of Age. Annals of Internal Medicine. 169: 233-239. PMID 30073297 DOI: 10.7326/M17-2832 |
0.01 |
|
| 2018 |
Rambow F, Rogiers A, Marin-Bejar O, Aibar S, Femel J, Dewaele M, Karras P, Brown D, Chang YH, Debiec-Rychter M, Adriaens C, Radaelli E, Wolter P, Bechter O, Dummer R, ... ... Flaherty KT, et al. Toward Minimal Residual Disease-Directed Therapy in Melanoma. Cell. PMID 30017245 DOI: 10.1016/J.Cell.2018.06.025 |
0.01 |
|
| 2018 |
Faje AT, Lawrence D, Flaherty K, Freedman C, Fadden R, Rubin K, Cohen J, Sullivan RJ. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. PMID 29975414 DOI: 10.1002/cncr.31629 |
0.01 |
|
| 2018 |
Ribas A, Kirkwood JM, Flaherty KT. Anti-PD-1 antibody treatment for melanoma. The Lancet. Oncology. 19: e219. PMID 29726378 DOI: 10.1016/S1470-2045(18)30202-X |
0.01 |
|
| 2018 |
Mooradian MJ, Reuben A, Prieto PA, Hazar-Rethinam M, Frederick DT, Nadres B, Piris A, Juneja V, Cooper ZA, Sharpe AH, Corcoran RB, Flaherty KT, Lawrence DP, Wargo JA, Sullivan RJ. A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. Oncoimmunology. 7: e1423172. PMID 29721378 DOI: 10.1080/2162402X.2017.1423172 |
0.01 |
|
| 2018 |
Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, ... ... Flaherty KT, et al. Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma. Embo Molecular Medicine. PMID 29650805 DOI: 10.15252/Emmm.201708446 |
0.01 |
|
| 2018 |
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, ... ... Flaherty KT, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. The Lancet. Oncology. PMID 29573941 DOI: 10.1016/S1470-2045(18)30142-6 |
0.01 |
|
| 2018 |
Zhang G, Wu LW, Mender I, Barzily-Rokni M, Hammond MR, Ope O, Cheng C, Randell S, Sadek N, Beroard A, Xiao M, Tian T, Tan J, Saeed U, Sugarman E, ... ... Flaherty KT, et al. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29563139 DOI: 10.1158/1078-0432.Ccr-17-2773 |
0.01 |
|
| 2018 |
Tolcher A, Flaherty K, Shapiro GI, Berlin J, Witzig T, Habermann T, Bullock A, Rock E, Elekes A, Lin C, Kostic D, Ohi N, Rasco D, Papadopoulos KP, Patnaik A, et al. A First-in-Human Phase 1 Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers. The Oncologist. PMID 29511132 DOI: 10.1634/Theoncologist.2017-0325 |
0.01 |
|
| 2018 |
Al Emran A, Marzese DM, Menon DR, Stark MS, Torrano J, Hammerlindl H, Zhang G, Brafford P, Salomon MP, Nelson N, Hammerlindl S, Gupta D, Mills GB, Lu Y, Sturm RA, ... Flaherty K, et al. Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget. 9: 8206-8222. PMID 29492189 DOI: 10.18632/Oncotarget.23654 |
0.01 |
|
| 2018 |
Moschos SJ, Sullivan RJ, Hwu WJ, Ramanathan RK, Adjei AA, Fong PC, Shapira-Frommer R, Tawbi HA, Rubino J, Rush TS, Zhang D, Miselis NR, Samatar AA, Chun P, Rubin EH, ... ... Flaherty KT, et al. Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors. Jci Insight. 3. PMID 29467321 DOI: 10.1172/jci.insight.92352 |
0.01 |
|
| 2018 |
Rahman R, Cortes A, Niemierko A, Oh KS, Flaherty KT, Lawrence DP, Sullivan RJ, Shih HA. The impact of timing of immunotherapy with cranial irradiation in melanoma patients with brain metastases: intracranial progression, survival and toxicity. Journal of Neuro-Oncology. PMID 29453679 DOI: 10.1007/s11060-018-2795-7 |
0.01 |
|
| 2018 |
Hong X, Sullivan RJ, Kalinich M, Kwan TT, Giobbie-Hurder A, Pan S, LiCausi JA, Milner JD, Nieman LT, Wittner BS, Ho U, Chen T, Kapur R, Lawrence DP, Flaherty KT, et al. Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy. Proceedings of the National Academy of Sciences of the United States of America. PMID 29453278 DOI: 10.1073/Pnas.1719264115 |
0.01 |
|
| 2018 |
McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, ... ... Flaherty KT, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. The Lancet. Oncology. PMID 29449192 DOI: 10.1016/S1470-2045(18)30078-0 |
0.01 |
|
| 2018 |
Jenkins RW, Barbie DA, Flaherty KT. Mechanisms of resistance to immune checkpoint inhibitors. British Journal of Cancer. 118: 9-16. PMID 29319049 DOI: 10.1038/bjc.2017.434 |
0.01 |
|
| 2018 |
Schadendorf D, Long GV, Grob JJ, Nathan PD, Ribas A, Davies MA, Flaherty K, Squires M, Jaeger S, Powell W, Tan P, Robert C. PD-L1 and CD8 expression and association with outcomes in patients (pts) with BRAF V600E/K–mutant metastatic melanoma (MM) who received dabrafenib + trametinib (D+T) in the randomized phase 3 COMBI-v study. Journal of Clinical Oncology. 36: 183-183. DOI: 10.1200/JCO.2018.36.5_SUPPL.183 |
0.01 |
|
| 2018 |
Cleary JM, Voss MH, Meric-Bernstam F, Hierro C, Heist RS, Ishii N, Kirpicheva Y, Nicolas-Metral V, Pokorska-Bocci A, Vaslin A, Venetz W, Zanna C, Flaherty K, Tabernero J, Baselga J. Safety and efficacy of the selective FGFR inhibitor debio 1347 in phase I study patients with FGFR genomically activated advanced biliary tract cancer (BTC). Journal of Clinical Oncology. 36: 447-447. DOI: 10.1200/JCO.2018.36.4_SUPPL.447 |
0.01 |
|
| 2018 |
Liu D, Zhang G, Shi A, Izar B, Heyde A, Kasumova GG, Frederick DT, Moll T, Sahu A, Ruppin E, Nowak M, Kellis M, Herlyn M, Lawrence DP, Flaherty K, et al. Phylogenetic analysis of longitudinal melanoma samples to reveal convergent evolution and markers of immunotherapy resistance. Journal of Clinical Oncology. 36: 9581-9581. DOI: 10.1200/Jco.2018.36.15_Suppl.9581 |
0.01 |
|
| 2018 |
Gogas H, Dummer R, Ascierto PA, Arance AM, Mandalà M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JW, Yamazaki N, Loquai C, ... ... Flaherty K, et al. Adverse events of special interest in the phase 3 COLUMBUS study. Journal of Clinical Oncology. 36: 9567-9567. DOI: 10.1200/JCO.2018.36.15_SUPPL.9567 |
0.01 |
|
| 2018 |
Park JC, Wirth LJ, Flaherty K, Lawrence DP, Demehri S, Kraft S, Foreman R, Clark JR, Cohen JV, Kim Y, Boland GM, Frederick DT, Sullivan RJ. Immune checkpoint inhibition (ICI) in advanced cutaneous squamous cell carcinoma (cSCC): Clinical response and correlative biomarker analysis. Journal of Clinical Oncology. 36: 9564-9564. DOI: 10.1200/Jco.2018.36.15_Suppl.9564 |
0.01 |
|
| 2018 |
Dummer R, Ascierto PA, Gogas H, Arance AM, Mandalà M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JW, Yamazaki N, Loquai C, ... ... Flaherty K, et al. Overall survival in COLUMBUS: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) vs vemurafenib (VEM) or enco in BRAF-mutant melanoma. Journal of Clinical Oncology. 36: 9504-9504. DOI: 10.1200/JCO.2018.36.15_SUPPL.9504 |
0.01 |
|
| 2018 |
Cohen JV, Misdraji J, Dougan M, Fadden R, Rubin KM, Lawless A, Reynolds KL, Lawrence DP, Mooradian M, Flaherty K, Sullivan RJ. Characterization of immune related hepatitis (irH) from immune checkpoint inhibitors (ICIs). Journal of Clinical Oncology. 36: 3087-3087. DOI: 10.1200/JCO.2018.36.15_SUPPL.3087 |
0.01 |
|
| 2018 |
Chat V, Ferguson R, Simpson D, Kazlow E, Lax R, Moran U, Wilson M, Pavlick AC, Sullivan RJ, Flaherty K, Osman I, Weber JS, Kirchhoff T. Autoimmune genetic variants as germline biomarkers of response in melanoma immunotherapy treatment. Journal of Clinical Oncology. 36: 3079-3079. DOI: 10.1200/JCO.2018.36.15_SUPPL.3079 |
0.01 |
|
| 2018 |
Izar B, Jerby-Arnon L, Rotem A, Shah P, Liu D, Zhang G, Schilling B, Rozenblatt-Rosen O, Boland GM, Hodi FS, Flaherty K, Van Allen EM, Johnson BE, Schadendorf D, Yoon C, et al. Single-cell RNA-sequencing and -imaging of melanoma ecosystems reveals sources of resistance to immune checkpoint blockade. Journal of Clinical Oncology. 36: 3074-3074. DOI: 10.1200/Jco.2018.36.15_Suppl.3074 |
0.01 |
|
| 2018 |
Chae YK, Vaklavas C, Cheng HH, Hong F, Harris L, Mitchell EP, Zwiebel JA, McShane L, Gray RJ, Li S, Ivy SP, Ansher SS, Hamilton SR, Williams PM, Tricoli JV, ... ... Flaherty K, et al. Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway. Journal of Clinical Oncology. 36: 2503-2503. DOI: 10.1200/Jco.2018.36.15_Suppl.2503 |
0.01 |
|
| 2018 |
Krop IE, Jegede O, Grilley-Olson JE, Lauring JD, Hamilton SR, Zwiebel JA, Li S, Rubinstein L, Doyle A, Patton DR, Mitchell EP, Arteaga CL, Conley BA, Sims D, Harris L, ... ... Flaherty K, et al. Results from molecular analysis for therapy choice (MATCH) arm I: Taselisib for PIK3CA-mutated tumors. Journal of Clinical Oncology. 36: 101-101. DOI: 10.1200/Jco.2018.36.15_Suppl.101 |
0.01 |
|
| 2018 |
Jhaveri KL, Makker V, Wang XV, Chen AP, Flaherty K, Conley BA, O'Dwyer PJ, Williams PM, Hamilton SR, Harris L, McShane L, Rubinstein L, Gray RJ, Li S, Mitchell EP, et al. Ado-trastuzumab emtansine (T-DM1) in patients (pts) with HER2 amplified (amp) tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the National Cancer Institute (NCI) Molecular Analysis for Therapy Choice (MATCH) trial. Journal of Clinical Oncology. 36: 100-100. DOI: 10.1200/Jco.2018.36.15_Suppl.100 |
0.01 |
|
| 2018 |
Carbone D, Sharpnack M, He K, Butterfield LH, Eggermont AMM, Gonzalez-Cao M, Karachaliou N, Crespo G, Aldeguer E, Drozdowskyj A, Giménez-Capitán A, Teixidó C, Molina-Vila MA, Ramírez SV, Algarra SM, ... ... Flaherty K, et al. Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts Journal of Translational Medicine. 16. DOI: 10.1186/S12967-017-1352-Z |
0.01 |
|
| 2018 |
Shi A, Cintolo-Gonzalez JA, Chien I, Frederick DT, Alpatov R, Michaud W, Plana D, Panka D, Corcoran R, Flaherty K, Sullivan R, Kellis M, Boland G. Abstract B25: Exosomal transcriptomic signatures tracks and predicts response to checkpoint blockade immunotherapy Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-B25 |
0.01 |
|
| 2018 |
Kasumova GG, Shi A, Cintolo-Gonzalez JA, Chein I, Frederick DT, Alpatov R, Michaud WA, Plana D, Panka DJ, Corcoran RB, Flaherty KT, Sullivan RJ, Kellis M, Boland GM. Abstract A35: BRAF inhibition increases exosomal PD-L1 protein expression in melanoma Cancer Immunology Research. 6. DOI: 10.1158/2326-6074.Tumimm17-A35 |
0.01 |
|
| 2018 |
Hong X, Sullivan RJ, Kalinich M, Kwan T, Pan S, LiCausi JA, Milner JD, Nieman LT, Wittner BS, Ho U, Chen T, Kapur R, Lawrence D, Flaherty KT, Sequist LV, et al. Abstract LB-144: Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-144 |
0.01 |
|
| 2018 |
Rasco D, Lakhani N, Sullivan R, Mita M, Shah J, Usansky H, Reddy S, Rao NS, Toker S, Denis L, Flaherty K, Tolcher A. Abstract CT019: ASN003, a novel highly selective BRAF and PI3K dual inhibitor: Phase I PK/PD results in patients with advanced solid tumors Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Ct019 |
0.01 |
|
| 2018 |
Menon DR, Hammerlindl H, Emran AA, Torrano J, Hammerlindl S, Zhang G, Somasundaram R, Sturm RA, Haass NK, Flaherty K, Herlyn M, Schaider H. Abstract 5833: Escape form adaptive drug tolerance through OGT and TET1 mediated H3K4me3 remodeling in MAPKi resistant melanoma Cancer Research. 78: 5833-5833. DOI: 10.1158/1538-7445.Am2018-5833 |
0.01 |
|
| 2018 |
Shi A, Kasumova G, Chien I, Cintolo-Gonzalez J, Frederick DT, Alpatov R, Michaud WA, Plana D, Corcoran R, Flaherty K, Sullivan R, Kellis M, Boland G. Abstract 4282: Deconvolution of plasma-derived exosomes for tracking and prediction of immunotherapy across multiple tissues Cancer Research. 78: 4282-4282. DOI: 10.1158/1538-7445.Am2018-4282 |
0.01 |
|
| 2018 |
Chen AP, O'Dwyer PJ, Harris L, Conley BA, Hamilton SR, Williams M, Gray RJ, Li S, McShane LM, Rubinstein LV, Lee SI, Kumar S, Mitchell EP, Zwiebel JA, Gatsonis CA, ... ... Flaherty KT, et al. Abstract PL03-01: NCI-MATCH: A new paradigm in the era of genomic oncology Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-Pl03-01 |
0.01 |
|
| 2018 |
Rasco D, Lakhani N, Sullivan R, Mita M, Shah J, Usansky H, Reddy S, Rao N, Denis LJ, Tolcher A, Flaherty K. Abstract B147: A phase 1 PK/PD study of ASN003, a novel, highly selective BRAF and PI3K dual inhibitor, in patients with advanced solid tumors Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B147 |
0.01 |
|
| 2018 |
Emran A, Marzese DM, Menon DR, Stark M, Torrano J, Hammerlindl H, Zhang G, Brafford P, Hammerlindl S, Gupta D, Mills GB, Lu Y, Flaherty K, Sturm R, Hoon DSB, et al. Distinct epigenetic remodelling defines early stress-induced drug tolerance in melanoma Australasian Journal of Dermatology. 59: 31-32. DOI: 10.1111/Ajd.16_12815 |
0.01 |
|
| 2018 |
Menon DR, Hammerlindl H, Emran A, Torrano J, Hammerlindl S, Zhang G, Krause L, Somasundaram R, Sturm R, Haass NK, Flaherty K, Herlyn M, Schaider H. 1237 Escape form adaptive drug tolerance through OGT and TET1 mediated H3K4me3 remodeling in MAPKi-resistant melanoma Journal of Investigative Dermatology. 138. DOI: 10.1016/J.Jid.2018.03.1252 |
0.01 |
|
| 2018 |
Rahman R, Niemierko A, Cortes A, Oh K, Flaherty K, Lawrence D, Sullivan R, Shih H. The use of Anti-PD1 Therapy in Melanoma Patients with Known Brain Metastases: Survival, Durable Intracranial Progression Free Survival and Radionecrosis International Journal of Radiation Oncology*Biology*Physics. 102: e275. DOI: 10.1016/J.IJROBP.2018.07.887 |
0.01 |
|
| 2017 |
Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, Patel MR, Shapiro GI, Mier JW, Tolcher AW, Wang-Gillam A, Sznol M, Flaherty K, Buchbinder E, Carvajal RD, et al. First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. Cancer Discovery. PMID 29247021 DOI: 10.1158/2159-8290.Cd-17-1119 |
0.01 |
|
| 2017 |
Singleton KR, Crawford L, Tsui E, Manchester HE, Maertens O, Liu X, Liberti MV, Magpusao AN, Stein EM, Tingley JP, Frederick DT, Boland GM, Flaherty KT, McCall SJ, Krepler C, et al. Melanoma Therapeutic Strategies that Select against Resistance by Exploiting MYC-Driven Evolutionary Convergence. Cell Reports. 21: 2796-2812. PMID 29212027 DOI: 10.1016/J.Celrep.2017.11.022 |
0.01 |
|
| 2017 |
Davies MA, Flaherty KT. Melanoma in 2017: Moving treatments earlier to move further forwards. Nature Reviews. Clinical Oncology. 15: 75-76. PMID 29182162 DOI: 10.1038/nrclinonc.2017.183 |
0.01 |
|
| 2017 |
O'Reilly EM, Roach J, Miller P, Yu KH, Tjan C, Rosano M, Krause S, Avery W, Wolf J, Flaherty K, Nix D, Ryan DP. Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results. The Oncologist. PMID 29158367 DOI: 10.1634/theoncologist.2017-0472 |
0.01 |
|
| 2017 |
Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, ... ... Flaherty KT, et al. A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma. Cell Reports. 21: 1953-1967. PMID 29141225 DOI: 10.1016/J.Celrep.2017.10.021 |
0.01 |
|
| 2017 |
Garman B, Anastopoulos IN, Krepler C, Brafford P, Sproesser K, Jiang Y, Wubbenhorst B, Amaravadi R, Bennett J, Beqiri M, Elder D, Flaherty KT, Frederick DT, Gangadhar TC, Guarino M, et al. Genetic and Genomic Characterization of 462 Melanoma Patient-Derived Xenografts, Tumor Biopsies, and Cell Lines. Cell Reports. 21: 1936-1952. PMID 29141224 DOI: 10.1016/J.Celrep.2017.10.052 |
0.01 |
|
| 2017 |
Wang GX, Kurra V, Gainor JF, Sullivan RJ, Flaherty KT, Lee SI, Fintelmann FJ. Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings. Radiographics : a Review Publication of the Radiological Society of North America, Inc. 37: 2132-2144. PMID 29131763 DOI: 10.1148/rg.2017170085 |
0.01 |
|
| 2017 |
Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, Bowden M, Deng J, Liu H, Miao D, He MX, Walker W, Zhang G, Tian T, Cheng C, ... ... Flaherty KT, et al. Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discovery. PMID 29101162 DOI: 10.1158/2159-8290.Cd-17-0833 |
0.01 |
|
| 2017 |
Sade-Feldman M, Jiao YJ, Chen JH, Rooney MS, Barzily-Rokni M, Eliane JP, Bjorgaard SL, Hammond MR, Vitzthum H, Blackmon SM, Frederick DT, Hazar-Rethinam M, Nadres BA, Van Seventer EE, Shukla SA, ... ... Flaherty KT, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nature Communications. 8: 1136. PMID 29070816 DOI: 10.1038/S41467-017-01062-W |
0.01 |
|
| 2017 |
Jilaveanu LB, Puligandla M, Weiss SA, Wang VX, Zito CR, Flaherty KT, Boeke M, Neumeister VM, Camp RL, Adeniran A, Pins M, Manola J, DiPaola RS, Haas N, Kluger HM. Tumor microvessel density as a prognostic marker in high-risk renal cell carcinoma patients treated on ECOG-ACRIN E2805. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29066509 DOI: 10.1158/1078-0432.Ccr-17-1555 |
0.01 |
|
| 2017 |
Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Ca: a Cancer Journal For Clinicians. PMID 29028110 DOI: 10.3322/caac.21409 |
0.01 |
|
| 2017 |
Long GV, Eroglu Z, Infante J, Patel S, Daud A, Johnson DB, Gonzalez R, Kefford R, Hamid O, Schuchter L, Cebon J, Sharfman W, McWilliams R, Sznol M, Redhu S, ... ... Flaherty KT, et al. Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017741025. PMID 28991513 DOI: 10.1200/JCO.2017.74.1025 |
0.01 |
|
| 2017 |
Bédard PL, Davies MA, Kopetz S, Juric D, Shapiro GI, Luke JJ, Spreafico A, Wu B, Castell C, Gomez C, Cartot-Cotton S, Mazuir F, Dubar M, Micallef S, Demers B, ... Flaherty KT, et al. First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors. Cancer. PMID 28976556 DOI: 10.1002/cncr.31044 |
0.01 |
|
| 2017 |
Chandonnet CJ, Boutwell KM, Spigel N, Carter J, DeGrazia M, Ozonoff A, Flaherty K. It's in Your Hands: An Educational Initiative to Improve Parent/Family Hand Hygiene Compliance. Dimensions of Critical Care Nursing : Dccn. 36: 327-333. PMID 28976482 DOI: 10.1097/DCC.0000000000000268 |
0.01 |
|
| 2017 |
Chapman PB, Robert C, Larkin J, Haanen JB, Ribas A, Hogg D, Hamid O, Ascierto PA, Testori A, Lorigan PC, Dummer R, Sosman JA, Flaherty KT, Chang I, Coleman S, et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: 2581-2587. PMID 28961848 DOI: 10.1093/annonc/mdx339 |
0.01 |
|
| 2017 |
Lu H, Liu S, Zhang G, Bin Wu, Zhu Y, Frederick DT, Hu Y, Zhong W, Randell S, Sadek N, Zhang W, Chen G, Cheng C, Zeng J, Wu LW, ... ... Flaherty KT, et al. PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas. Nature. PMID 28953887 DOI: 10.1038/Nature24040 |
0.01 |
|
| 2017 |
Somasundaram R, Zhang G, Fukunaga-Kalabis M, Perego M, Krepler C, Xu X, Wagner C, Hristova D, Zhang J, Tian T, Wei Z, Liu Q, Garg K, Griss J, Hards R, ... ... Flaherty K, et al. Tumor-associated B-cells induce tumor heterogeneity and therapy resistance. Nature Communications. 8: 607. PMID 28928360 DOI: 10.1038/S41467-017-00452-4 |
0.01 |
|
| 2017 |
Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, Gavert N, Zwang Y, Cooper ZA, Shee K, Thaiss CA, Reuben A, Livny J, Avraham R, Frederick DT, ... ... Flaherty KT, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science (New York, N.Y.). 357: 1156-1160. PMID 28912244 DOI: 10.1126/Science.Aah5043 |
0.01 |
|
| 2017 |
Ugurel S, Röhmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C. Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. European Journal of Cancer (Oxford, England : 1990). 83: 247-257. PMID 28756137 DOI: 10.1016/j.ejca.2017.06.028 |
0.01 |
|
| 2017 |
Kraft S, Fernandez-Figueras MT, Richarz NA, Flaherty KT, Hoang MP. PDL1 expression in desmoplastic melanoma is associated with tumor aggressiveness and progression. Journal of the American Academy of Dermatology. PMID 28728868 DOI: 10.1016/j.jaad.2017.05.007 |
0.01 |
|
| 2017 |
Niessner H, Sinnberg T, Kosnopfel C, Smalley KSM, Beck D, Praetorius C, Mai M, Beissert S, Kulms D, Schaller M, Garbe C, Flaherty KT, Westphal D, Wanke I, Meier F. BRAF inhibitors amplify the pro-apoptotic activity of MEK inhibitors by inducing ER stress in NRAS-mutant melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28724666 DOI: 10.1158/1078-0432.CCR-17-0098 |
0.01 |
|
| 2017 |
Izar B, Sharfman W, Hodi FS, Lawrence D, Flaherty KT, Amaravadi R, Kim KB, Puzanov I, Sosman J, Dummer R, Goldinger SM, Lam L, Kakar S, Tang Z, Krieter O, et al. A first-in-human phase I, multicenter, open-label, dose-escalation study of the oral RAF/VEGFR-2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. Cancer Medicine. PMID 28719152 DOI: 10.1002/cam4.1140 |
0.01 |
|
| 2017 |
Schadendorf D, Long GV, Stroiakovski D, Karaszewska B, Hauschild A, Levchenko E, Chiarion-Sileni V, Schachter J, Garbe C, Dutriaux C, Gogas H, Mandalà M, Haanen JBAG, Lebbé C, Mackiewicz A, ... ... Flaherty KT, et al. Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials. European Journal of Cancer (Oxford, England : 1990). 82: 45-55. PMID 28648698 DOI: 10.1016/J.Ejca.2017.05.033 |
0.01 |
|
| 2017 |
Smith MP, Rowling EJ, Miskolczi Z, Ferguson J, Spoerri L, Haass NK, Sloss O, McEntegart S, Arozarena I, von Kriegsheim A, Rodriguez J, Brunton H, Kmarashev J, Levesque MP, Dummer R, ... ... Flaherty KT, et al. Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure. Embo Molecular Medicine. PMID 28606996 DOI: 10.15252/Emmm.201607156 |
0.01 |
|
| 2017 |
Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Márquez-Rodas I, Del Vecchio M, Lebbé C, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. The Lancet. Oncology. PMID 28592387 DOI: 10.1016/S1470-2045(17)30429-1 |
0.01 |
|
| 2017 |
Bartucci M, Hussein MS, Huselid E, Flaherty K, Patrizii M, Laddha SV, Kui C, Bigos RA, Gilleran JA, El Ansary MMS, Awad MAM, Kimball SD, Augeri DJ, Sabaawy HE. Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular Carcinoma. Targeted Oncology. PMID 28589491 DOI: 10.1007/s11523-017-0501-x |
0.01 |
|
| 2017 |
Flaherty KT, Le DT, Lemery S. Tissue-Agnostic Drug Development. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 37: 222-230. PMID 28561648 DOI: 10.14694/EDBK_173855 |
0.01 |
|
| 2017 |
Betof AS, Nipp RD, Giobbie-Hurder A, Johnpulle RAN, Rubin K, Rubinstein SM, Flaherty KT, Lawrence DP, Johnson DB, Sullivan RJ. Impact of Age on Outcomes with Immunotherapy for Patients with Melanoma. The Oncologist. PMID 28476944 DOI: 10.1634/theoncologist.2016-0450 |
0.01 |
|
| 2017 |
Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28475671 DOI: 10.1093/Annonc/Mdx176 |
0.01 |
|
| 2017 |
Zhang D, Zhang G, Hu X, Wu L, Feng Y, He S, Zhang Y, Hu Z, Yang L, Tian T, Xu W, Wei Z, Lu Y, Flaherty KT, Zhong X, et al. Oncogenic RAS regulates long non-coding RNA Orilnc1 in human cancer. Cancer Research. PMID 28473531 DOI: 10.1158/0008-5472.Can-16-1768 |
0.01 |
|
| 2017 |
Larimer BM, Wehrenberg-Klee E, Dubois F, Mehta A, Kalomeris T, Flaherty K, Boland G, Mahmood U. Granzyme B PET Imaging as a Predictive Biomarker of Immunotherapy Response. Cancer Research. 77: 2318-2327. PMID 28461564 DOI: 10.1158/0008-5472.CAN-16-3346 |
0.01 |
|
| 2017 |
Young HL, Rowling EJ, Bugatti M, Giurisato E, Luheshi N, Arozarena I, Acosta JC, Kamarashev J, Frederick DT, Cooper ZA, Reuben A, Gil J, Flaherty KT, Wargo JA, Vermi W, et al. An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition. The Journal of Experimental Medicine. PMID 28450382 DOI: 10.1084/jem.20160855 |
0.01 |
|
| 2017 |
Friedman AA, Xia Y, Trippa L, Le LP, Igras V, Frederick DT, Wargo JA, Tanabe KK, Lawrence DP, Neuberg DS, Flaherty KT, Fisher D. Feasibility of ultra-high-throughput functional screening of melanoma biopsies for discovery of novel cancer drug combinations. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28446504 DOI: 10.1158/1078-0432.Ccr-16-3029 |
0.01 |
|
| 2017 |
Vitiello M, Tuccoli A, D'Aurizio R, Sarti S, Giannecchini L, Lubrano S, Marranci A, Evangelista M, Peppicelli S, Ippolito C, Barravecchia I, Guzzolino E, Montagnani V, Gowen M, Mercoledi E, ... ... Flaherty K, et al. Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget. 8: 25395-25417. PMID 28445987 DOI: 10.18632/Oncotarget.15915 |
0.01 |
|
| 2017 |
Luke JJ, Flaherty KT, Ribas A, Long GV. Targeted agents and immunotherapies: optimizing outcomes in melanoma. Nature Reviews. Clinical Oncology. PMID 28374786 DOI: 10.1038/nrclinonc.2017.43 |
0.01 |
|
| 2017 |
Frankel AE, Flaherty KT, Weiner GJ, Chen R, Azad NS, Pishvaian MJ, Thompson JA, Taylor MH, Mahadevan D, Lockhart AC, Vaishampayan UN, Berlin JD, Smith DC, Sarantopoulos J, Riese M, et al. Academic Cancer Center Phase I Program Development. The Oncologist. PMID 28314841 DOI: 10.1634/Theoncologist.2016-0409 |
0.01 |
|
| 2017 |
Dummer R, Schadendorf D, Ascierto PA, Arance A, Dutriaux C, Di Giacomo AM, Rutkowski P, Del Vecchio M, Gutzmer R, Mandala M, Thomas L, Demidov L, Garbe C, Hogg D, Liszkay G, ... ... Flaherty K, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. The Lancet. Oncology. PMID 28284557 DOI: 10.1016/S1470-2045(17)30180-8 |
0.01 |
|
| 2017 |
Haas NB, Manola J, Dutcher JP, Flaherty KT, Uzzo RG, Atkins MB, DiPaola RS, Choueiri TK. Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial. Jama Oncology. 3: 1249-1252. PMID 28278333 DOI: 10.1001/jamaoncol.2017.0076 |
0.01 |
|
| 2017 |
Chen Y, Liu YC, Sung YC, Ramjiawan RR, Lin TT, Chang CC, Jeng KS, Chang CF, Liu CH, Gao DY, Hsu FF, Duyverman AM, Kitahara S, Huang P, Dima S, ... ... Flaherty KT, et al. Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Scientific Reports. 7: 44123. PMID 28276530 DOI: 10.1038/Srep44123 |
0.01 |
|
| 2017 |
Koetz-Ploch L, Hanniford D, Dolgalev I, Sokolova E, Zhong J, Díaz-Martínez M, Bernstein E, Darvishian F, Flaherty KT, Chapman PB, Tawbi H, Hernando E. MicroRNA-125a promotes resistance to BRAF inhibitors through suppression of the intrinsic apoptotic pathway. Pigment Cell & Melanoma Research. PMID 28140520 DOI: 10.1111/Pcmr.12578 |
0.01 |
|
| 2017 |
O'Reilly EM, Mahalingam D, Roach JM, Miller PJ, Rosano ME, Krause S, Avery W, Bekaii-Saab TS, Shao SH, Richards DA, Vaickus L, Wolf J, Flaherty K, Ryan DP. Necuparanib combined with nab-paclitaxel + gemcitabine in patients with metastatic pancreatic cancer: Phase 2 results. Journal of Clinical Oncology. 35: 370-370. DOI: 10.1200/JCO.2017.35.4_SUPPL.370 |
0.01 |
|
| 2017 |
Mooradian M, Cohen JV, Giobbie-Hurder A, Fadden R, Rubin KM, Flaherty K, Lawrence DP, Sullivan RJ. Inflammatory arthritis: An under-recognized immune-relate adverse effect. Journal of Clinical Oncology. 35: e14565-e14565. DOI: 10.1200/JCO.2017.35.15_SUPPL.E14565 |
0.01 |
|
| 2017 |
Rasco DW, Sullivan RJ, Lakhani NJ, Reddy S, Rao NS, Denis LJ, Tolcher AW, Flaherty K. ASN003, a highly selective BRAF and PI3K inhibitor: Preclinical and phase 1 clinical data in patients with advanced solid tumors. Journal of Clinical Oncology. 35: e14102-e14102. DOI: 10.1200/JCO.2017.35.15_SUPPL.E14102 |
0.01 |
|
| 2017 |
Larkin JMG, Lewis KD, Ribas A, Flaherty K, Ascierto PA, Dréno B, Mckenna EF, Zhu Q, Mun Y, Hauschild A, McArthur GA. Impact of gene expression profiles on clinical predictors of survival in patients (pts) with BRAFV600-mutated metastatic melanoma (mM). Journal of Clinical Oncology. 35: 9556-9556. DOI: 10.1200/JCO.2017.35.15_SUPPL.9556 |
0.01 |
|
| 2017 |
Edenfield WJ, Becerra C, Braiteh FS, Spira AI, Sullivan RJ, Panella TJ, Li W, Huang J, Li Y, Flaherty K, Hitron M, Li C. A phase Ib study of napabucasin plus weekly paclitaxel in patients with advanced melanoma. Journal of Clinical Oncology. 35: 9553-9553. DOI: 10.1200/JCO.2017.35.15_SUPPL.9553 |
0.01 |
|
| 2017 |
Davies MA, Robert C, Long GV, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, Moschos SJ, Hogg D, Marquez Rodas I, Del Vecchio M, Lebbe C, et al. COMBI-MB: A phase II study of combination dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant (mut) melanoma brain metastases (MBM). Journal of Clinical Oncology. 35: 9506-9506. DOI: 10.1200/JCO.2017.35.15_SUPPL.9506 |
0.01 |
|
| 2017 |
Long GV, Eroglu Z, Infante JR, Patel SP, Daud A, Johnson DB, Gonzalez R, Kefford R, Hamid O, Schuchter LM, Cebon JS, Sharfman WH, McWilliams RR, Sznol M, Weber JS, ... ... Flaherty KT, et al. Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM). Journal of Clinical Oncology. 35: 9505-9505. DOI: 10.1200/JCO.2017.35.15_SUPPL.9505 |
0.01 |
|
| 2017 |
Miller WH, Kim TM, Lee CB, Flaherty KT, Reddy S, Jamal R, Chow LQ, Rooney IA, Pitcher B, Cha E, Infante JR. Atezolizumab (A) + cobimetinib (C) in metastatic melanoma (mel): Updated safety and clinical activity. Journal of Clinical Oncology. 35: 3057-3057. DOI: 10.1200/Jco.2017.35.15_Suppl.3057 |
0.01 |
|
| 2017 |
Ferguson R, Simpson D, Martinez CN, Vogelsang M, Kazlow E, Moran U, Weber JS, Sullivan RJ, Flaherty K, Pavlick AC, Ribas A, Osman I, Kirchhoff T. Expression quantitative trait loci (eQTLs) as germline determinants of melanoma immunotherapy response. Journal of Clinical Oncology. 35: 3017-3017. DOI: 10.1200/JCO.2017.35.15_SUPPL.3017 |
0.01 |
|
| 2017 |
Li BT, Janku F, Patel MR, Sullivan RJ, Flaherty K, Buchbinder EI, Lacouture ME, Varghese AM, Wong DJL, Sznol M, Sosman JA, Keedy VL, Wang-Gillam A, Ribas A, Tolcher AW, et al. First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study. Journal of Clinical Oncology. 35: 2508-2508. DOI: 10.1200/Jco.2017.35.15_Suppl.2508 |
0.01 |
|
| 2017 |
Hong DS, Hollebecque A, Gordon MS, Flaherty KT, Shapiro G, Rodon J, Millward M, Ramdas N, Zhang W, Gao L, Sykes A, Willard MD, Yu D, Schade A, Flynn DL, et al. A first-in-human dose phase 1 study of LY3009120 in advanced cancer patients. Journal of Clinical Oncology. 35: 2507-2507. DOI: 10.1200/Jco.2017.35.15_Suppl.2507 |
0.01 |
|
| 2017 |
Voss MH, Hierro C, Heist RS, Cleary JM, Meric-Bernstam F, Gandhi L, Ishii N, Kirpicheva Y, Nicolas-Metral V, Pokorska-Bocci A, Purcea D, Vaslin A, Moulon C, Zanna C, Flaherty K, et al. Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors. Journal of Clinical Oncology. 35: 2500-2500. DOI: 10.1200/JCO.2017.35.15_SUPPL.2500 |
0.01 |
|
| 2017 |
Sullivan RJ, Janku F, Li BT, Wong D, Sosman J, Keedy V, Buchbinder E, Tolcher A, Varghese A, Hyman DM, Flaherty KT, Ribas A, Carvajal R, Wang-Gillam A, Kluger H, et al. Abstract CT003: Activity of the ERK1/2 inhibitor ulixertinib (BVD-523) in patients withBRAFandNRASmutant melanoma Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ct003 |
0.01 |
|
| 2017 |
Alvarez-Breckenridge C, Giobbie-Hurder A, Gill C, Bertalan M, Stocking J, Kaplan A, Nayyar N, Lawrence D, Flaherty K, Shih H, Oh K, Batchelor T, Cahill D, Sullivan R, Brastianos P. Cmet-16. The Role Of Surgical Resection Of Melanoma Brain Metastases In The Immunotherapy Era Neuro-Oncology. 19. DOI: 10.1093/Neuonc/Nox168.165 |
0.01 |
|
| 2017 |
Gasal E, Fernandez AMA, Ascierto PA, Atkinson V, Dummer R, Flaherty KT, Grob J, Hansson J, Hassel J, Larkin J, Lebbé C, Long GV, Lorigan P, Miller W, Nathan P, et al. 1259TiPA randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600–mutant melanoma (COMBI-i) Annals of Oncology. 28. DOI: 10.1093/Annonc/Mdx377.044 |
0.01 |
|
| 2017 |
Gogas H, Dummer R, Ascierto P, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsová I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot J, Yamazaki N, Loquai C, ... ... Flaherty K, et al. Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma Annals of Oncology. 28: v442. DOI: 10.1093/ANNONC/MDX377.031 |
0.01 |
|
| 2017 |
Arance A, Dummer R, Ascierto P, Gogas H, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsová I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot J, Yamazaki N, Loquai C, ... ... Flaherty K, et al. Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma Annals of Oncology. 28: v441. DOI: 10.1093/ANNONC/MDX377.030 |
0.01 |
|
| 2017 |
Lewis K, Larkin J, Ribas A, Flaherty K, McArthur G, Ascierto P, Dréno B, McKenna E, Zhu Q, Mun Y, Hauschild A. Impact of duration of response (DOR) on overall survival (OS) in patients with metastatic melanoma treated with dacarbazine (DTIC), vemurafenib (V), or cobimetinib plus vemurafenib (C+V): a pooled analysis Annals of Oncology. 28: v440. DOI: 10.1093/ANNONC/MDX377.027 |
0.01 |
|
| 2017 |
Schadendorf D, Flaherty K, Nathan P, Hersey P, Garbe C, Milhem M, Demidov L, Mohr P, Hassel J, Rutkowski P, Dummer R, Utikal J, Kiecker F, Larkin J, D’Amelio A, et al. Five-year efficacy and safety update from METRIC: Trametinib vs chemotherapy in patients with BRAF V600E/K–mutant advanced or metastatic melanoma Annals of Oncology. 28: v435. DOI: 10.1093/ANNONC/MDX377.013 |
0.01 |
|
| 2017 |
Dummer R, Ascierto P, Gogas H, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsová I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot J, Yamazaki N, Loquai C, ... ... Flaherty K, et al. Results of COLUMBUS Part 2: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus ENCO in BRAF-mutant melanoma Annals of Oncology. 28: v429-v430. DOI: 10.1093/ANNONC/MDX377.002 |
0.01 |
|
| 2017 |
Rasco D, Sullivan R, Lakhani N, Reddy S, Rao N, Denis L, Tolcher A, Flaherty K. A Phase 1 PK/PD Study of ASN003, a novel highly selective BRAF and PI3K inhibitor, in patients with advanced solid tumors Annals of Oncology. 28: v124. DOI: 10.1093/annonc/mdx367.005 |
0.01 |
|
| 2017 |
Rahman R, Cortes A, Oh K, Flaherty K, Lawrence D, Sullivan R, Shih H. The Impact of Timing of Immunotherapy with Cranial Irradiation on Early Distant Brain Progression and Overall Survival in Patients with Melanoma Brain Metastases International Journal of Radiation Oncology*Biology*Physics. 99: E101-E102. DOI: 10.1016/J.IJROBP.2017.06.833 |
0.01 |
|
| 2016 |
Long GV, Grob JJ, Nathan P, Ribas A, Robert C, Schadendorf D, Lane SR, Mak C, Legenne P, Flaherty KT, Davies MA. Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. The Lancet. Oncology. PMID 27864013 DOI: 10.1016/S1470-2045(16)30578-2 |
0.01 |
|
| 2016 |
Scanlon P, Flaherty K, Reilly EA, Barth EG, Potter-Bynoe G, Cardini J, Riley AM, McAdam AJ, Sandora TJ. Association Between Storage Interval and Contamination of Reprocessed Flexible Endoscopes in a Pediatric Gastrointestinal Procedural Unit. Infection Control and Hospital Epidemiology. 1-5. PMID 27817757 DOI: 10.1017/ice.2016.260 |
0.01 |
|
| 2016 |
Khalil DN, Postow MA, Ibrahim N, Ludwig DL, Cosaert J, Kambhampati SR, Tang S, Grebennik D, Kauh JS, Lenz HJ, Flaherty KT, Hodi FS, Lawrence DP, Wolchok JD. An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27797971 DOI: 10.1158/1078-0432.Ccr-16-1241 |
0.01 |
|
| 2016 |
Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, ... ... Flaherty K, et al. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. PMID 27602582 DOI: 10.18632/Oncotarget.11814 |
0.01 |
|
| 2016 |
Scarlett UK, Chang DC, Murtagh TJ, Flaherty KT. High-Throughput Testing of Novel-Novel Combination Therapies for Cancer: An Idea Whose Time Has Come. Cancer Discovery. 6: 956-62. PMID 27587468 DOI: 10.1158/2159-8290.CD-16-0440 |
0.01 |
|
| 2016 |
Lawrence NF, Hammond MR, Frederick DT, Su Y, Dias-Santagata D, Deng A, Selim MA, Mahalingam M, Flaherty KT, Hoang MP. Ki-67, p53, and p16 expression, and G691S RET polymorphism in desmoplastic melanoma (DM): A clinicopathologic analysis of predictors of outcome. Journal of the American Academy of Dermatology. 75: 595-602. PMID 27543214 DOI: 10.1016/j.jaad.2016.04.059 |
0.01 |
|
| 2016 |
Rose AA, Annis MG, Frederick DT, Biondini M, Dong Z, Kwong LN, Chin L, Keler T, Hawthorne T, Watson IR, Flaherty KT, Siegel PM. MAPK Pathway Inhibitors Sensitize BRAF Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27515299 DOI: 10.1158/1078-0432.Ccr-16-1192 |
0.01 |
|
| 2016 |
Shen CH, Kim SH, Trousil S, Frederick DT, Piris A, Yuan P, Cai L, Gu L, Li M, Lee JH, Mitra D, Fisher DE, Sullivan RJ, Flaherty KT, Zheng B. Loss of cohesin complex components STAG2 or STAG3 confers resistance to BRAF inhibition in melanoma. Nature Medicine. PMID 27500726 DOI: 10.1038/Nm.4155 |
0.01 |
|
| 2016 |
Nanda VGY, Peng W, Hwu P, Davies MA, Ciliberto G, Fattore L, Malpicci D, Aurisicchio L, Ascierto PA, Croce CM, Mancini R, Spranger S, Gajewski TF, Wang Y, Ferrone S, ... ... Flaherty KT, et al. Melanoma and Immunotherapy Bridge 2015 : Naples, Italy. 1-5 December 2015 Journal of Translational Medicine. 14: 65-65. PMID 27461275 DOI: 10.1186/S12967-016-0791-2 |
0.01 |
|
| 2016 |
Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, ... ... Flaherty KT, et al. Corrigendum: sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. PMID 27383789 DOI: 10.1038/Nature18939 |
0.01 |
|
| 2016 |
Weber ML, Liang MC, Flaherty KT, Heier JS. Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer. Jama Ophthalmology. PMID 27309887 DOI: 10.1001/jamaophthalmol.2016.0090 |
0.01 |
|
| 2016 |
Bansal N, Bartucci M, Yusuff S, Davis S, Flaherty K, Huselid E, Patrizii M, Jones D, Cao L, Sydorenko N, Moon YC, Zhong H, Medina D, Kerrigan J, Stein MN, et al. BMI-1 targeting interferes with patient-derived tumor-initiating cell survival and tumor growth in prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27307599 DOI: 10.1158/1078-0432.Ccr-15-3107 |
0.01 |
|
| 2016 |
Niessner H, Schmitz J, Tabatabai G, Schmid A, Calaminus C, Sinnberg T, Weide B, Eigentler TK, Garbe C, Schittek B, Quintanilla-Fend L, Bender B, Mai M, Praetorius C, Beissert S, ... ... Flaherty KT, et al. PI3K pathway inhibition achieves potent antitumor activity in melanoma brain metastases in vitro and in vivo. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27307593 DOI: 10.1158/1078-0432.CCR-16-0064 |
0.01 |
|
| 2016 |
Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Hilton JF, Nasir A, Beckmann RP, Schade AE, Fulford AD, Nguyen TS, ... ... Flaherty KT, et al. Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors. Cancer Discovery. PMID 27217383 DOI: 10.1158/2159-8290.CD-16-0095 |
0.01 |
|
| 2016 |
Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, ... ... Flaherty KT, et al. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology. 5: e1136044. PMID 27141370 DOI: 10.1080/2162402X.2015.1136044 |
0.01 |
|
| 2016 |
Tirosh I, Izar B, Prakadan SM, Wadsworth MH, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G, Fallahi-Sichani M, Dutton-Regester K, Lin JR, Cohen O, Shah P, ... ... Flaherty KT, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science (New York, N.Y.). 352: 189-196. PMID 27124452 DOI: 10.1126/Science.Aad0501 |
0.01 |
|
| 2016 |
Jonas O, Oudin MJ, Kosciuk T, Whitman M, Gertler FB, Cima MJ, Flaherty KT, Langer R. Parallel in-vivo assessment of drug phenotypes at various time points during systemic BRAF inhibition reveals tumor adaptation and altered treatment vulnerabilities. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27091406 DOI: 10.1158/1078-0432.Ccr-15-2722 |
0.01 |
|
| 2016 |
Merlino G, Herlyn M, Fisher DE, Bastian BC, Flaherty KT, Davies MA, Wargo JA, Curiel-Lewandrowski C, Weber MJ, Leachman SA, Soengas MS, McMahon M, Harbour JW, Swetter SM, Aplin AE, et al. The state of melanoma: challenges and opportunities. Pigment Cell & Melanoma Research. PMID 27087480 DOI: 10.1111/Pcmr.12475 |
0.01 |
|
| 2016 |
Tateishi K, Iafrate AJ, Ho Q, Curry WT, Batchelor T, Flaherty KT, Onozato M, Lelic N, Sundaram S, Cahill DP, Chi AS, Wakimoto H. Myc-driven glycolysis is a therapeutic target in glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27076630 DOI: 10.1158/1078-0432.CCR-15-2274 |
0.01 |
|
| 2016 |
Kato S, Lippman SM, Flaherty KT, Kurzrock R. The Conundrum of Genetic "Drivers" in Benign Conditions. Journal of the National Cancer Institute. 108. PMID 27059373 DOI: 10.1093/Jnci/Djw036 |
0.01 |
|
| 2016 |
Zhang G, Frederick DT, Wu L, Wei Z, Krepler C, Srinivasan S, Chae YC, Xu X, Choi H, Dimwamwa E, Ope O, Shannan B, Basu D, Zhang D, Guha M, ... ... Flaherty KT, et al. Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors. The Journal of Clinical Investigation. PMID 27043285 DOI: 10.1172/Jci82661 |
0.01 |
|
| 2016 |
Kaur A, Webster MR, Marchbank K, Behera R, Ndoye A, Kugel CH, Dang VM, Appleton J, O'Connell MP, Cheng P, Valiga AA, Morissette R, McDonnell NB, Ferrucci L, Kossenkov AV, ... ... Flaherty KT, et al. sFRP2 in the aged microenvironment drives melanoma metastasis and therapy resistance. Nature. PMID 27042933 DOI: 10.1038/Nature17392 |
0.01 |
|
| 2016 |
Miller MA, Oudin MJ, Sullivan RJ, Wang SJ, Meyer AS, Im H, Frederick DT, Tadros J, Griffith LG, Lee H, Weissleder R, Flaherty KT, Gertler FB, Lauffenburger DA. Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance. Cancer Discovery. PMID 26984351 DOI: 10.1158/2159-8290.Cd-15-0933 |
0.01 |
|
| 2016 |
Smith MP, Brunton H, Rowling EJ, Ferguson J, Arozarena I, Miskolczi Z, Lee JL, Girotti MR, Marais R, Levesque MP, Dummer R, Frederick DT, Flaherty KT, Cooper ZA, Wargo JA, et al. Inhibiting Drivers of Non-mutational Drug Tolerance Is a Salvage Strategy for Targeted Melanoma Therapy. Cancer Cell. 29: 270-284. PMID 26977879 DOI: 10.1016/J.Ccell.2016.02.003 |
0.01 |
|
| 2016 |
Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England). PMID 26969090 DOI: 10.1016/S0140-6736(16)00559-6 |
0.01 |
|
| 2016 |
Roh MR, Gupta S, Park KH, Chung KY, Lauss M, Flaherty KT, Jönsson G, Rha SY, Tsao H. Promoter Methylation of PTEN is a Significant Prognostic Factor in Melanoma Survival. The Journal of Investigative Dermatology. PMID 26854490 DOI: 10.1016/j.jid.2016.01.024 |
0.01 |
|
| 2016 |
Sabbatino F, Wang Y, Scognamiglio G, Favoino E, Feldman SA, Villani V, Flaherty KT, Nota S, Giannarelli D, Simeone E, Anniciello AM, Palmieri G, Pepe S, Botti G, Ascierto PA, et al. Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma. Journal of the National Cancer Institute. 108. PMID 26851802 DOI: 10.1093/Jnci/Djv435 |
0.01 |
|
| 2016 |
Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, Kefford RF, Lawrence D, Kudchadkar R, Burris HA, Falchook GS, ... ... Flaherty KT, et al. Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26811525 DOI: 10.1200/JCO.2015.62.9345 |
0.01 |
|
| 2016 |
Eliades P, Miller DM, Miao B, Kumar R, Taylor M, Buch S, Srinivasa SP, Flaherty KT, Tsao H. A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. Cancer Biology & Therapy. 0. PMID 26810603 DOI: 10.1080/15384047.2016.1139267 |
0.01 |
|
| 2016 |
Flaherty KT, Sosman JA, Atkins MB. New options and new questions: how to select and sequence therapies for patients with metastatic melanoma. American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 524-30. PMID 24451790 DOI: 10.14694/EdBook_AM.2012.32.524 |
0.01 |
|
| 2016 |
Haas NB, Manola J, Uzzo RG, Flaherty K, Pins M, Messing EM, DiPaola RS. A multivariate analysis of prognostic factors from assure (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma. Journal of Clinical Oncology. 34: 618-618. DOI: 10.1200/Jco.2016.34.2_Suppl.618 |
0.01 |
|
| 2016 |
Conley BA, Chen AP, O'Dwyer PJ, Arteaga CL, Hamilton SR, Williams PM, Little RF, Takebe N, Patton D, Sazali K, Zhang J, Zwiebel JA, Mitchell EP, Gray RJ, McShane L, ... ... Flaherty K, et al. NCI-MATCH (Molecular Analysis for Therapy Choice) – a national signal finding trial. Journal of Clinical Oncology. 34. DOI: 10.1200/Jco.2016.34.15_Suppl.Tps2606 |
0.01 |
|
| 2016 |
McQuade JL, Haydu LE, Frankian S, Spencer C, Long GV, Grob JJ, Lane SR, Legenne P, Flaherty K, Hwu P, Hess KR, Davies MA. The impact of obesity on outcomes in metastatic melanoma (MM) patients (pts) treated with dabrafenib and trametinib. Journal of Clinical Oncology. 34: 9566-9566. DOI: 10.1200/JCO.2016.34.15_SUPPL.9566 |
0.01 |
|
| 2016 |
Sullivan RJ, Barbash Z, Edelheit O, Vidne M, Sosman JA, Flaherty K, Davies MA, Johnson DB, Tarcic G. Functional characterization of non-V600 BRAF mutations and their response to Trametinib (Tram). Journal of Clinical Oncology. 34: 9537-9537. DOI: 10.1200/Jco.2016.34.15_Suppl.9537 |
0.01 |
|
| 2016 |
Larkin JMG, Ribas A, Flaherty K, McArthur GA, Ascierto PA, Dréno B, Lewis KD, Chapman PB, Mckenna EF, Zhu Q, Mun Y, Hauschild A. Identifying prognostic subgroups for outcomes in BRAFV600-mutated metastatic melanoma patients (pts) treated with vemurafenib (V) ± cobimetinib (C): A pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM. Journal of Clinical Oncology. 34: 9536-9536. DOI: 10.1200/JCO.2016.34.15_SUPPL.9536 |
0.01 |
|
| 2016 |
Grob JJ, Flaherty K, Long GV, Nathan PD, Schadendorf D, Ribas A, Robert C, Lane SR, Mak C, Legenne P, Davies MA. Pooled analysis of safety over time and link between adverse events and efficacy across combination dabrafenib and trametinib (D+T) registration trials. Journal of Clinical Oncology. 34: 9534-9534. DOI: 10.1200/JCO.2016.34.15_SUPPL.9534 |
0.01 |
|
| 2016 |
Flaherty K, Davies MA, Grob JJ, Long GV, Nathan PD, Ribas A, Robert C, Schadendorf D, Frederick DT, Hammond MR, Jane-Valbuena J, Mu XJ, Squires M, Jaeger SA, Lane SR, et al. Genomic analysis and 3-y efficacy and safety update of COMBI-d: A phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. Journal of Clinical Oncology. 34: 9502-9502. DOI: 10.1200/Jco.2016.34.15_Suppl.9502 |
0.01 |
|
| 2016 |
Dummer R, Schadendorf D, Ascierto PA, Arance Fernández AM, Dutriaux C, Maio M, Rutkowski P, Del Vecchio M, Gutzmer R, Mandalà M, Thomas L, Wasserman E, Ford J, Weill M, Sirulnik LA, ... ... Flaherty K, et al. Results of NEMO: A phase III trial of binimetinib (BINI) vs dacarbazine (DTIC) in NRAS-mutant cutaneous melanoma. Journal of Clinical Oncology. 34: 9500-9500. DOI: 10.1200/JCO.2016.34.15_SUPPL.9500 |
0.01 |
|
| 2016 |
Kurra V, Sullivan RJ, Gainor JF, Hodi FS, Gandhi L, Sadow CA, Harris GJ, Flaherty K, Lee S. Pseudoprogression in cancer immunotherapy: Rates, time course and patient outcomes. Journal of Clinical Oncology. 34: 6580-6580. DOI: 10.1200/Jco.2016.34.15_Suppl.6580 |
0.01 |
|
| 2016 |
Bendell JC, Kim TW, Goh BC, Wallin J, Oh D, Han S, Lee CB, Hellmann MD, Desai J, Lewin JH, Solomon BJ, Chow LQM, Miller WH, Gainor JF, Flaherty K, et al. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC). Journal of Clinical Oncology. 34: 3502-3502. DOI: 10.1200/Jco.2016.34.15_Suppl.3502 |
0.01 |
|
| 2016 |
Coticchia CM, Sullivan RJ, Hurley JD, Hu L, Lawrence DP, Flaherty K, Blackmon SM, Brock G, O'Neill VJ, Skog J. Association of plasma exosomal mRNA changes with long-term durable response to ipilimumab (IPI) in metastatic melanoma (MM) patients. Journal of Clinical Oncology. 34: 3037-3037. DOI: 10.1200/Jco.2016.34.15_Suppl.3037 |
0.01 |
|
| 2016 |
Krepler C, Sproesser K, Beqiri M, Xiao M, Brafford P, Xu W, Garman B, Wargo J, Davies MA, Frederick DT, Flaherty KT, Hoon D, Bennett JJ, Guarino M, Petrelli NJ, et al. Abstract A01: A comprehensive collection of patient derived xenografts of human melanoma with clinical, genomic, and biological characterization Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Pdx16-A01 |
0.01 |
|
| 2016 |
Conley BA, Gray R, Chen A, O’Dwyer P, Arteaga C, Coffey B, Patton D, Li S, McShane LM, Rubinstein L, Comis R, Abrams J, Williams PM, Lih C, Hamilton S, ... ... Flaherty K, et al. Abstract CT101: NCI-molecular analysis for therapy choice (NCI-MATCH) clinical trial: interim analysis Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Ct101 |
0.01 |
|
| 2016 |
Sabbatino F, Wang Y, Scognamiglio G, Favoino E, Feldman SA, Villani V, Flaherty KT, Nota S, Giannarelli D, Simeone E, Anniciello AM, Palmieri G, Pepe S, Botti G, Ascierto PA, et al. Abstract 4017: Anti-tumor activity of a BRAF inhibitor and IFNα combination in BRAF mutant melanoma Cancer Research. 76: 4017-4017. DOI: 10.1158/1538-7445.Am2016-4017 |
0.01 |
|
| 2016 |
Rose AAN, Annis MG, Frederick DT, Dong Z, Kwong L, Keller T, Hawthorne T, Watson IR, Flaherty KT, Siegel PM. Abstract 296: Targeting the melanosome: overcoming MAPK-inhibitor resistance in melanoma Cancer Research. 76: 296-296. DOI: 10.1158/1538-7445.Am2016-296 |
0.01 |
|
| 2016 |
Ascierto P, Ribas A, Larkin J, McArthur G, Lewis K, Hauschild A, Flaherty K, McKenna E, Zhu Q, Mun Y, Dréno B. Prognostic subgroups and impact of treatment for post-progression overall survival (ppOS) in patients (pts) with BRAFV600-mutated metastatic melanoma treated with dacarbazine (DTIC) or vemurafenib (VEM) ± cobimetinib (COBI): A pooled analysis Annals of Oncology. 27: vi391. DOI: 10.1093/ANNONC/MDW379.37 |
0.01 |
|
| 2016 |
Robert C, Schadendorf D, Long G, Stroyakovskiy D, Levchenko E, Chiarion-Sileni V, Flaherty K, Nathan P, Ribas A, Davies M, Zhang J, Chen L, Mookerjee B, Redhu S, Grob J. Analysis of patient-reported outcomes by disease progression status in patients (pts) with BRAF V600–mutant metastatic melanoma in the COMBI-d and COMBI-v trials Annals of Oncology. 27: vi390. DOI: 10.1093/ANNONC/MDW379.35 |
0.01 |
|
| 2016 |
Grob J, Robert C, Long G, Stroyakovskiy D, Levchenko E, Chiarion-Sileni V, Flaherty K, Nathan P, Ribas A, Davies M, Zhang J, Chen L, Mookerjee B, Redhu S, Schadendorf D. Health-related quality-of-life (HRQOL) impact of dabrafenib (D) and trametinib (T) vs BRAF inhibitor (BRAFi) monotherapy by lactate dehydrogenase (LDH) in patients (pts) with BRAF V600–mutant melanoma Annals of Oncology. 27: vi389. DOI: 10.1093/ANNONC/MDW379.32 |
0.01 |
|
| 2016 |
Davies M, Grob J, Long G, Flaherty K, Nathan P, Ribas A, Schadendorf D, Mookerjee B, Legos J, Lane S, Robert C. Pooled analysis of factors to predict durable clinical outcomes with combination dabrafenib (D) and trametinib (T) across registration trials Annals of Oncology. 27: vi388. DOI: 10.1093/Annonc/Mdw379.29 |
0.01 |
|
| 2016 |
Cooper ZA, Reuben A, Spencer CN, Prieto PA, Austin-Breneman JL, Jiang H, Haymaker C, Gopalakrishnan V, Tetzlaff MT, Frederick DT, Sullivan RJ, Amaria RN, Patel SP, Hwu P, Woodman SE, ... ... Flaherty KT, et al. Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma Oncoimmunology. 5. DOI: 10.1080/2162402X.2015.1136044 |
0.01 |
|
| 2016 |
Smith M, Brunton H, Rowling E, Girotti M, Marais R, Dummer R, Flaherty K, Cooper Z, Wargo J, Wellbrock C. Proffered Paper: Utilising non-mutational drug-tolerance prolongs and improves targeted melanoma therapy European Journal of Cancer. 61: S2-S3. DOI: 10.1016/S0959-8049(16)61005-5 |
0.01 |
|
| 2016 |
Chen A, Conley B, Hamilton S, Williams M, O'Dwyer P, Arteaga C, Gray R, McShane L, Li S, Rubinstein L, Patton D, Sazali K, Zwiebel J, Mitchell E, Smith M, ... ... Flaherty K, et al. NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial: A novel public-private partnership European Journal of Cancer. 69: S137. DOI: 10.1016/S0959-8049(16)33006-4 |
0.01 |
|
| 2016 |
Buchbinder EI, Flaherty KT. Biomarkers in Melanoma: Lessons from Translational Medicine Trends in Cancer. 2: 305-312. DOI: 10.1016/j.trecan.2016.05.003 |
0.01 |
|
| 2015 |
Eliades P, Flaherty KT, Tsao H. Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma. Melanoma Management. 2: 133-147. PMID 30190843 DOI: 10.2217/mmt.15.5 |
0.01 |
|
| 2015 |
Betof AS, Rubin KM, Blackmon SM, Flaherty K, Lawrence DP, Sullivan RJ. Palliative care and hospice use among melanoma patients treated with immunotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 116. PMID 28148099 DOI: 10.1200/jco.2015.33.29_suppl.116 |
0.01 |
|
| 2015 |
Flaherty KT. New drugs in development for melanoma. Clinical Advances in Hematology & Oncology : H&O. 13: 717-9. PMID 27058694 |
0.01 |
|
| 2015 |
Ugurel S, Röhmel J, Ascierto PA, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Long GV, Lorigan P, McArthur GA, Ribas A, Robert C, Schadendorf D, Garbe C. Survival of patients with advanced metastatic melanoma: The impact of novel therapies. European Journal of Cancer (Oxford, England : 1990). 53: 125-134. PMID 26707829 DOI: 10.1016/j.ejca.2015.09.013 |
0.01 |
|
| 2015 |
Tateishi K, Wakimoto H, Iafrate AJ, Tanaka S, Loebel F, Lelic N, Wiederschain D, Bedel O, Deng G, Zhang B, He T, Shi X, Gerszten RE, Zhang Y, Yeh JR, ... ... Flaherty KT, et al. Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. Cancer Cell. 28: 773-84. PMID 26678339 DOI: 10.1016/J.Ccell.2015.11.006 |
0.01 |
|
| 2015 |
Friedman AA, Letai A, Fisher DE, Flaherty KT. Precision medicine for cancer with next-generation functional diagnostics. Nature Reviews. Cancer. PMID 26536825 DOI: 10.1038/Nrc4015 |
0.01 |
|
| 2015 |
Fofaria NM, Frederick DT, Sullivan RJ, Flaherty KT, Srivastava SK. Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma. Oncotarget. PMID 26497853 DOI: 10.18632/oncotarget.5755 |
0.01 |
|
| 2015 |
Friedman AA, Amzallag A, Pruteanu-Malinici I, Baniya S, Cooper ZA, Piris A, Hargreaves L, Igras V, Frederick DT, Lawrence DP, Haber DA, Flaherty KT, Wargo JA, Ramaswamy S, Benes CH, et al. Landscape of Targeted Anti-Cancer Drug Synergies in Melanoma Identifies a Novel BRAF-VEGFR/PDGFR Combination Treatment. Plos One. 10: e0140310. PMID 26461489 DOI: 10.1371/Journal.Pone.0140310 |
0.01 |
|
| 2015 |
Santiago-Walker A, Gagnon R, Mazumdar J, Casey M, Long GV, Schadendorf D, Flaherty KT, Kefford RF, Hauschild A, Hwu P, Haney P, O'Hagan A, Carver J, Goodman V, Legos J, et al. Correlation of BRAF mutation status in circulating-free DNA and tumor and association with clinical outcome across four BRAFi and MEKi clinical trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26446943 DOI: 10.1158/1078-0432.Ccr-15-0321 |
0.01 |
|
| 2015 |
Grob JJ, Long GV, Schadendorf D, Flaherty K. Disease kinetics for decision-making in advanced melanoma: A call for scenario-driven strategy trials The Lancet Oncology. 16: e522-e526. PMID 26433825 DOI: 10.1016/S1470-2045(15)00003-0 |
0.01 |
|
| 2015 |
Grob JJ, Amonkar MM, Karaszewska B, Schachter J, Dummer R, Mackiewicz A, Stroyakovskiy D, Drucis K, Grange F, Chiarion-Sileni V, Rutkowski P, Lichinitser M, Levchenko E, Wolter P, Hauschild A, ... ... Flaherty K, et al. Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. The Lancet. Oncology. 16: 1389-98. PMID 26433819 DOI: 10.1016/S1470-2045(15)00087-X |
0.01 |
|
| 2015 |
Sullivan RJ, Flaherty KT. Immunotherapy: Anti-PD-1 therapies-a new first-line option in advanced melanoma. Nature Reviews. Clinical Oncology. 12: 625-6. PMID 26416151 DOI: 10.1038/nrclinonc.2015.170 |
0.01 |
|
| 2015 |
Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, Elco CP, Lee N, Juneja VR, Zhan Q, Lian CG, Thomi R, Hoetzenecker W, Cozzio A, Dummer R, ... ... Flaherty KT, et al. Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth. Cell. 162: 1242-56. PMID 26359984 DOI: 10.1016/J.Cell.2015.08.052 |
0.01 |
|
| 2015 |
Cao J, Dai X, Wan L, Wang H, Zhang J, Goff PS, Sviderskaya EV, Xuan Z, Xu Z, Xu X, Hinds P, Flaherty KT, Faller DV, Goding CR, Wang Y, et al. The E3 ligase APC/CCdh1 promotes ubiquitylation-mediated proteolysis of PAX3 to suppress melanocyte proliferation and melanoma growth. Science Signaling. 8: ra87. PMID 26329581 DOI: 10.1126/Scisignal.Aab1995 |
0.01 |
|
| 2015 |
Wilson MA, Zhao F, Khare S, D'Andrea K, Wubbenhorst B, Roszik J, Woodman SE, Rimm DL, Kirkwood JM, Kluger HM, Schuchter LM, Lee SJ, Flaherty KT, Nathanson KL. Copy number changes are associated with response to treatment with carboplatin, paclitaxel, and sorafenib in melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26307133 DOI: 10.1158/1078-0432.Ccr-15-1162 |
0.01 |
|
| 2015 |
Fedorenko IV, Wargo JA, Flaherty KT, Messina JL, Smalley KS. BRAF Inhibition Generates a Host-Tumor Niche that Mediates Therapeutic Escape. The Journal of Investigative Dermatology. 135: 3115-24. PMID 26302068 DOI: 10.1038/jid.2015.329 |
0.01 |
|
| 2015 |
Lo JA, Fisher DE, Flaherty KT. Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy. Jama Oncology. PMID 26270186 DOI: 10.1001/jamaoncol.2015.2274 |
0.01 |
|
| 2015 |
Amaravadi RK, Hamilton KE, Ma X, Piao S, Del Portillo A, Nathanson KL, Carlino MS, Long GV, Puzanov I, Xu X, Morrissette JD, Tsai KY, Flaherty KT, Sosman J, Goodman GR, et al. Multiple gastrointestinal polyps in patients treated with BRAF inhibitors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26202952 DOI: 10.1158/1078-0432.Ccr-15-0469 |
0.01 |
|
| 2015 |
Mochel MC, Hammond MR, Frederick DT, Alora-Palli MB, Piris A, Flaherty KT, Hoang MP. Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients. Journal of the American Academy of Dermatology. PMID 26190239 DOI: 10.1016/j.jaad.2015.06.006 |
0.01 |
|
| 2015 |
Flaherty KT, Hamilton BK, Rosen MA, Amaravadi RK, Schuchter LM, Gallagher M, Chen H, Sehgal C, O'Dwyer PJ. Phase I/II Trial of Imatinib and Bevacizumab in Patients With Advanced Melanoma and Other Advanced Cancers. The Oncologist. PMID 26084808 DOI: 10.1634/Theoncologist.2015-0108 |
0.01 |
|
| 2015 |
Flaherty KT, Manola JB, Pins M, McDermott DF, Atkins MB, Dutcher JJ, George DJ, Margolin KA, DiPaola RS. BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma-A Trial of the ECOG-ACRIN Cancer Research Group (E2804). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 2384-91. PMID 26077237 DOI: 10.1200/JCO.2015.60.9727 |
0.01 |
|
| 2015 |
Fedorenko IV, Abel EV, Koomen JM, Fang B, Wood ER, Chen YA, Fisher KJ, Iyengar S, Dahlman KB, Wargo JA, Flaherty KT, Sosman JA, Sondak VK, Messina JL, Gibney GT, et al. Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells. Oncogene. PMID 26073081 DOI: 10.1038/Onc.2015.188 |
0.01 |
|
| 2015 |
Villaruz LC, Huang G, Romkes M, Kirkwood JM, Buch SC, Nukui T, Flaherty KT, Lee SJ, Wilson MA, Nathanson KL, Benos PV, Tawbi HA. MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603. Clinical Epigenetics. 7: 58. PMID 26052356 DOI: 10.1186/S13148-015-0092-2 |
0.01 |
|
| 2015 |
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, ... ... Flaherty K, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet (London, England). 386: 444-51. PMID 26037941 DOI: 10.1016/S0140-6736(15)60898-4 |
0.01 |
|
| 2015 |
Flaherty KT, Wargo JA, Bivona TG. YAP in MAPK pathway targeted therapy resistance. Cell Cycle (Georgetown, Tex.). 14: 1765-6. PMID 26036142 DOI: 10.1080/15384101.2015.1032644 |
0.01 |
|
| 2015 |
Sullivan RJ, Flaherty KT. New strategies in melanoma: entering the era of combinatorial therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2424-35. PMID 26034218 DOI: 10.1158/1078-0432.CCR-14-1650 |
0.01 |
|
| 2015 |
Vizoso M, Ferreira HJ, Lopez-Serra P, Carmona FJ, Martínez-Cardús A, Girotti MR, Villanueva A, Guil S, Moutinho C, Liz J, Portela A, Heyn H, Moran S, Vidal A, Martinez-Iniesta M, ... ... Flaherty KT, et al. Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR. Nature Medicine. PMID 26030178 DOI: 10.1038/Nm.3863 |
0.01 |
|
| 2015 |
Kim H, Frederick DT, Levesque MP, Cooper ZA, Feng Y, Krepler C, Brill L, Samuels Y, Hayward NK, Perlina A, Piris A, Zhang T, Halaban R, Herlyn MM, Brown KM, ... ... Flaherty KT, et al. Downregulation of the Ubiquitin Ligase RNF125 Underlies Resistance of Melanoma Cells to BRAF Inhibitors via JAK1 Deregulation. Cell Reports. 11: 1458-73. PMID 26027934 DOI: 10.1016/J.Celrep.2015.04.049 |
0.01 |
|
| 2015 |
Verduzco D, Flaherty KT, Smalley KS. Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma. Experimental Dermatology. 24: 657-8. PMID 26010519 DOI: 10.1111/exd.12763 |
0.01 |
|
| 2015 |
Sullivan RJ, Ibrahim N, Lawrence DP, Aldridge J, Giobbie-Hurder A, Hodi FS, Flaherty KT, Conley C, Mier JW, Atkins MB, McDermott DF. A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma. The Oncologist. 20: 617-8. PMID 25986244 DOI: 10.1634/theoncologist.2015-0105 |
0.01 |
|
| 2015 |
Puzanov I, Amaravadi RK, McArthur GA, Flaherty KT, Chapman PB, Sosman JA, Ribas A, Shackleton M, Hwu P, Chmielowski B, Nolop KB, Lin PS, Kim KB. Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. European Journal of Cancer (Oxford, England : 1990). 51: 1435-43. PMID 25980594 DOI: 10.1016/J.Ejca.2015.04.010 |
0.01 |
|
| 2015 |
Haas N, Manola J, Ky B, Flaherty KT, Uzzo RG, Kane C, Jewett MA, Wood L, Wood CG, Atkins MB, Dutcher JP, Wilding G, DiPaola R. Effects of adjuvant sorafenib and sunitinib on cardiac function in renal cell carcinoma patients without overt metastases:results from ASSURE, ECOG2805. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 25967143 DOI: 10.1158/1078-0432.Ccr-15-0215 |
0.01 |
|
| 2015 |
Sullivan RJ, Flaherty KT. Pembrolizumab for Treatment of Patients with Advanced or Unresectable Melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 2892-7. PMID 25931451 DOI: 10.1158/1078-0432.CCR-14-3061 |
0.01 |
|
| 2015 |
Wattson DA, Sullivan RJ, Niemierko A, Merritt RM, Lawrence DP, Oh KS, Flaherty KT, Shih HA. Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era. Journal of Neuro-Oncology. 123: 75-84. PMID 25864098 DOI: 10.1007/s11060-015-1761-x |
0.01 |
|
| 2015 |
Flaherty KT. When are signal transduction targeted therapies acting as immunotherapy? Cancer Biology and Therapy. 16: 645-647. PMID 25807058 DOI: 10.1080/15384047.2015.1030553 |
0.01 |
|
| 2015 |
Schadendorf D, Amonkar MM, Stroyakovskiy D, Levchenko E, Gogas H, de Braud F, Grob JJ, Bondarenko I, Garbe C, Lebbe C, Larkin J, Chiarion-Sileni V, Millward M, Arance A, Mandalà M, ... Flaherty KT, et al. Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanoma. European Journal of Cancer (Oxford, England : 1990). 51: 833-40. PMID 25794603 DOI: 10.1016/j.ejca.2015.03.004 |
0.01 |
|
| 2015 |
Ji Z, Erin Chen Y, Kumar R, Taylor M, Jenny Njauw CN, Miao B, Frederick DT, Wargo JA, Flaherty KT, Jönsson G, Tsao H. MITF Modulates Therapeutic Resistance through EGFR Signaling. The Journal of Investigative Dermatology. 135: 1863-72. PMID 25789707 DOI: 10.1038/Jid.2015.105 |
0.01 |
|
| 2015 |
Jones PS, Cahill DP, Brastianos PK, Flaherty KT, Curry WT. Ipilimumab and craniotomy in patients with melanoma and brain metastases: a case series. Neurosurgical Focus. 38: E5. PMID 25727227 DOI: 10.3171/2014.12.FOCUS14698 |
0.01 |
|
| 2015 |
Kwong LN, Boland GM, Frederick DT, Helms TL, Akid AT, Miller JP, Jiang S, Cooper ZA, Song X, Seth S, Kamara J, Protopopov A, Mills GB, Flaherty KT, Wargo JA, et al. Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. The Journal of Clinical Investigation. 125: 1459-70. PMID 25705882 DOI: 10.1172/Jci78954 |
0.01 |
|
| 2015 |
Flaherty KT. Effectively targeting CRAF: Rational serendipity targeting SRC? Pigment Cell and Melanoma Research. 28: 242-243. PMID 25677495 DOI: 10.1111/pcmr.12360 |
0.01 |
|
| 2015 |
Ribas A, Flaherty KT. Gauging the Long-Term Benefits of Ipilimumab in Melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 33: 1865-6. PMID 25667273 DOI: 10.1200/JCO.2014.59.5041 |
0.01 |
|
| 2015 |
Lin L, Sabnis AJ, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang MM, Karachaliou N, Cao MG, Manzano JL, ... ... Flaherty KT, et al. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nature Genetics. 47: 250-6. PMID 25665005 DOI: 10.1038/Ng.3218 |
0.01 |
|
| 2015 |
Lorigan P, Ascierto PA, Dummer R, Eggermont AM, Flaherty KT, Garbe C, Gogas H, Hauschild A, Kefford RF, Kirkwood JM, Larkin J, Long GV, Maio M, McArthur GA, Ribas A, et al. Expanded access programmes: patient interests versus clinical trial integrity. The Lancet. Oncology. 16: 15-7. PMID 25638540 DOI: 10.1016/S1470-2045(14)71161-1 |
0.01 |
|
| 2015 |
Miao B, Ji Z, Tan L, Taylor M, Zhang J, Choi HG, Frederick DT, Kumar R, Wargo JA, Flaherty KT, Gray NS, Tsao H. EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanoma. Cancer Discovery. 5: 274-87. PMID 25542448 DOI: 10.1158/2159-8290.Cd-14-0295 |
0.01 |
|
| 2015 |
Paraiso KH, Das Thakur M, Fang B, Koomen JM, Fedorenko IV, John JK, Tsao H, Flaherty KT, Sondak VK, Messina JL, Pasquale EB, Villagra A, Rao UN, Kirkwood JM, Meier F, et al. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discovery. 5: 264-73. PMID 25542447 DOI: 10.1158/2159-8290.Cd-14-0293 |
0.01 |
|
| 2015 |
Kinlay J, Flaherty K, Scanlon P, Mehrotra P, Potter-Bynoe G, Sandora TJ. Barriers to the use of face protection for standard precautions by health care providers American Journal of Infection Control. 43: 169-170. PMID 25516218 DOI: 10.1016/j.ajic.2014.11.002 |
0.01 |
|
| 2015 |
Menzies AM, Ashworth MT, Swann S, Kefford RF, Flaherty K, Weber J, Infante JR, Kim KB, Gonzalez R, Hamid O, Schuchter L, Cebon J, Sosman JA, Little S, Sun P, et al. Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 415-21. PMID 25411413 DOI: 10.1093/annonc/mdu529 |
0.01 |
|
| 2015 |
Webster MR, Xu M, Kinzler KA, Kaur A, Appleton J, O'Connell MP, Marchbank K, Valiga A, Dang VM, Perego M, Zhang G, Slipicevic A, Keeney F, Lehrmann E, Wood W, ... ... Flaherty KT, et al. Wnt5A promotes an adaptive, senescent-like stress response, while continuing to drive invasion in melanoma cells. Pigment Cell & Melanoma Research. 28: 184-95. PMID 25407936 DOI: 10.1111/Pcmr.12330 |
0.01 |
|
| 2015 |
Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild A, Lorigan P, ... ... Flaherty K, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. The New England Journal of Medicine. 372: 30-9. PMID 25399551 DOI: 10.1056/NEJMoa1412690 |
0.01 |
|
| 2015 |
Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, Gutkind JS, Bowcock AM, Streicher HZ, Patel PM, Sato T, Sossman JA, Sznol M, Welch J, Thurin M, ... ... Flaherty KT, et al. Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell & Melanoma Research. 28: 135-47. PMID 25113308 DOI: 10.1111/Pcmr.12304 |
0.01 |
|
| 2015 |
Sullivan RJ, Ibrahim N, Lawrence DP, Aldridge J, Giobbie-Hurder A, Stephen Hodi F, Flaherty KT, Conley C, Mier JW, Atkins MB, McDermott DF. A phase I trial of bortezomib and sorafenib in advanced malignant melanoma Oncologist. 20: 617-618. DOI: 10.1634/theoncologist.2015-0105 |
0.01 |
|
| 2015 |
Haas NB, Manola J, Uzzo RG, Atkins MB, Wilding G, Pins M, Jewett MAS, Kane CJ, Cella D, Wagner LI, Coomes B, Wood CG, Dutcher JP, Flaherty K, DiPaola RS. Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial. Journal of Clinical Oncology. 33: 403-403. DOI: 10.1200/Jco.2015.33.7_Suppl.403 |
0.01 |
|
| 2015 |
Hurley J, Hu L, Brock G, Sinclair I, Sullivan RJ, O'Neill VJ, Skog J, Flaherty K. Profiling exosomal mRNAs in patients undergoing immunotherapy for malignant melanoma. Journal of Clinical Oncology. 33: e22159-e22159. DOI: 10.1200/JCO.2015.33.15_SUPPL.E22159 |
0.01 |
|
| 2015 |
Wargo JA, Lawrence DP, Cooper ZA, Frederick DT, Giobbie-Hurder A, Piris A, Rubin KM, Fadden R, Reuben A, Starker L, Flaherty K, Sharpe A, Sullivan RJ. A phase II study of combined therapy with vemurafenib (vem) and high-dose interleukin-2 (aldesleukin; HD IL-2) in patients with metastatic melanoma. Journal of Clinical Oncology. 33: e20074-e20074. DOI: 10.1200/Jco.2015.33.15_Suppl.E20074 |
0.01 |
|
| 2015 |
Daud A, Weber JS, Sosman JA, Kim K, Gonzalez R, Hamid O, Infante JR, Cebon JS, Schuchter LM, Long GV, Algazi AP, Kudchadkar RR, Puzanov I, Lawrence DP, Kefford R, ... ... Flaherty K, et al. Updated overall survival (OS) results for BRF113220, a phase I–II study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM). Journal of Clinical Oncology. 33: 9036-9036. DOI: 10.1200/JCO.2015.33.15_SUPPL.9036 |
0.01 |
|
| 2015 |
Sullivan RJ, O'Neill VJ, Brinkmann K, Enderle D, Koestler T, Spiel A, Emenegger J, Noerholm M, Skog J, Berking C, Flaherty K. Plasma-based monitoring of BRAF mutations during therapy for malignant melanoma (MM) using combined exosomal RNA and cell-free DNA analysis. Journal of Clinical Oncology. 33: 9017-9017. DOI: 10.1200/JCO.2015.33.15_SUPPL.9017 |
0.01 |
|
| 2015 |
Haas NB, Manola J, Flaherty K, Uzzo RG, Atkins MB, Dutcher JP, Wood CG, Kane CJ, Jewett MAS, Coomes B, Matin SF, Kuzel T, Sexton WJ, Wong Y, Choueiri TK, et al. Dose analysis of ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase 3 trial. Journal of Clinical Oncology. 33: 4508-4508. DOI: 10.1200/Jco.2015.33.15_Suppl.4508 |
0.01 |
|
| 2015 |
O'Reilly EM, Mahalingam D, Roach JM, Schultes BC, Rosano ME, Miller PJ, Wolf J, Flaherty K, Ryan DP. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Phase 1 results. Journal of Clinical Oncology. 33: 4114-4114. DOI: 10.1200/JCO.2015.33.15_SUPPL.4114 |
0.01 |
|
| 2015 |
Jonker DJ, Laurie SA, Cote GM, Flaherty K, Fuchs CS, Chugh R, Smith DC, Edenfield WJ, Conkling PR, Mier JW, Goodwin RA, Kwak EL, Abrams TA, Goel R, Cleary JM, et al. Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer. Journal of Clinical Oncology. 33: 3615-3615. DOI: 10.1200/Jco.2015.33.15_Suppl.3615 |
0.01 |
|
| 2015 |
Bedard PL, Davies MA, Kopetz S, Flaherty KT, Shapiro G, Luke JJ, Spreafico A, Wu B, Gomez C, Cartot-Cotton S, Mazuir F, Micallef S, Demers B, Juric D. First-in-human phase I trial of the PI3Kb-selective inhibitor SAR260301 in patients with advanced solid tumors (NCT01673737). Journal of Clinical Oncology. 33: 2564-2564. DOI: 10.1200/JCO.2015.33.15_SUPPL.2564 |
0.01 |
|
| 2015 |
Infante JR, Janku F, Tolcher AW, Patel MR, Sullivan RJ, Flaherty K, Carvajal RD, Varghese AM, Wong DJL, Sznol M, Sosman JA, Wang-Gillam A, Burris HA, Ribas A, Patel SP, et al. Dose escalation stage of a first-in-class phase I study of the novel oral ERK 1/2 kinase inhibitor BVD-523 (ulixertinib) in patients with advanced solid tumors. Journal of Clinical Oncology. 33: 2506-2506. DOI: 10.1200/Jco.2015.33.15_Suppl.2506 |
0.01 |
|
| 2015 |
O'Neill VJ, Enderle D, Wheler JJ, Koestler T, Berking C, Skog J, Noerholm M, Flaherty K, Janku F. Detection of low abundant somatic mutations in circulating exosomal RNA and cfDNA with next-generation sequencing. Journal of Clinical Oncology. 33: 11061-11061. DOI: 10.1200/JCO.2015.33.15_SUPPL.11061 |
0.01 |
|
| 2015 |
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, De Braud FG, Larkin JMG, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, DeMarini DJ, ... ... Flaherty K, et al. Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/Kmutation-positive cutaneous melanoma. Journal of Clinical Oncology. 33: 102-102. DOI: 10.1200/JCO.2015.33.15_SUPPL.102 |
0.01 |
|
| 2015 |
Ribas A, Flaherty KT. Gauging the long-term benefits of ipilimumab in melanoma Journal of Clinical Oncology. 33: 1865-1866. DOI: 10.1200/JCO.2014.59.5041 |
0.01 |
|
| 2015 |
Powderly J, Cote G, Flaherty K, Szmulewitz RZ, Ribas A, Weber J, Loo D, Baughman J, Chen F, Moore P, Bonvini E, Vasselli J, Wigginton J, Cohen R, Burris H, et al. Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3 Journal For Immunotherapy of Cancer. 3: O8. DOI: 10.1186/2051-1426-3-S2-O8 |
0.01 |
|
| 2015 |
Kwong LN, Boland G, Frederick DT, Helms T, Miller JP, Jiang S, Cooper ZA, Protopopov A, Mills GB, Flaherty K, Wargo JA, Chin L. Abstract PR06: A co-clinical assessment of patterns of BRAF inhibitor resistance Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-Pr06 |
0.01 |
|
| 2015 |
Johannessen C, Konieczkowski D, Abudayyeh O, Kim JW, Cooper Z, Piris A, Frederick D, Barzily-Rokni M, Straussman R, Haq R, Fisher D, Mesirov J, Hahn W, Flaherty K, Wargo J, et al. Abstract PR04: A melanoma transcriptional state distinction influences sensitivity to MAPK pathway inhibitors Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Pms14-Pr04 |
0.01 |
|
| 2015 |
Kaur A, Marchbank K, Dang V, O'Connell M, Webster M, Appleton J, Cheng P, Valiga A, Morissette R, McDonnell N, Ferrucci L, Kossenkov A, Meeth K, Bosenberg M, Tang H, ... ... Flaherty K, et al. Abstract A04: Aging microenvironment modulates melanoma invasion and metastasis Cancer Research. 75. DOI: 10.1158/1538-7445.Mel2014-A04 |
0.01 |
|
| 2015 |
Lin L, Sabnis A, Chan E, Olivas V, Cade L, Pazarentzos E, Asthana S, Neel D, Yan JJ, Lu X, Pham L, Wang M, Karachaliou N, Cao MG, Manzano JL, ... ... Flaherty KT, et al. Abstract LB-239: The Hippo effector YAP promotes resistance to RAF and MEK targeted therapies Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-239 |
0.01 |
|
| 2015 |
Garman B, Krepler C, Sproesser K, Brafford P, Wilson M, Wubbenhorst B, Amaravadi R, Bennett J, Beqiri M, Davies M, Elder D, Flaherty K, Frederick D, Gangadhar TC, Guarino M, et al. Abstract 4668: Targeted, massively parallel sequencing identifies novel genetic subsets of cutaneous melanoma Cancer Research. 75: 4668-4668. DOI: 10.1158/1538-7445.Am2015-4668 |
0.01 |
|
| 2015 |
Kwong LN, Boland G, Frederick D, Helms T, Akid A, Miller J, Jiang S, Cooper Z, Song X, Seth S, Kamara J, Protopopov A, Mills G, Flaherty K, Wargo J, et al. Abstract 2841: A co-clinical assessment of patterns of BRAF inhibitor resistance Cancer Research. 75: 2841-2841. DOI: 10.1158/1538-7445.Am2015-2841 |
0.01 |
|
| 2015 |
Coticchia CM, Sullivan RJ, Flaherty KT, Hurley JD, Hu L, Blackmon SM, Brock G, O'Neill VT, Skog J. Abstract LB-C05: Early exosome mRNA changes are associated with improved progression free survival of metastatic melanoma patents on ipilimumab: Identification of a novel exosome mRNA signature of ipilimumab response Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-Lb-C05 |
0.01 |
|
| 2015 |
Cote G, Papadopoulos K, Patnaik A, Rascoe D, Smith L, Bullock A, Flaherty K, Shapiro G, Berlin J, Monga M, Habermann T, Witzig T, Lin C, Tsai L, Elekes A, et al. Abstract B118: A phase 1, open-label multiple dose escalation trial to determine safety and tolerability of once daily OPB-111077 in subjects with advanced cancer Molecular Cancer Therapeutics. 14. DOI: 10.1158/1535-7163.Targ-15-B118 |
0.01 |
|
| 2015 |
Verduzco D, Flaherty KT, Smalley KSM. Feeling energetic? New strategies to prevent metabolic reprogramming in melanoma Experimental Dermatology. 24: 657-658. DOI: 10.1111/exd.12763 |
0.01 |
|
| 2015 |
Aquilanti E, Gill C, Santagata S, Lawrence D, Flaherty K, Cahill D, Sullivan R, Brastianos P. BMET-04LEPTOMENINGEAL CARCINOMATOSIS IN MELANOMA Neuro-Oncology. 17: v45.4-v45. DOI: 10.1093/Neuonc/Nov208.04 |
0.01 |
|
| 2015 |
Fedorenko IV, Wargo JA, Flaherty KT, Messina JL, Smalley KSM. BRAF inhibition generates a host-tumor niche that mediates therapeutic escape Journal of Investigative Dermatology. 135: 3115-3124. DOI: 10.1038/jid.2015.329 |
0.01 |
|
| 2015 |
Hurley J, Hu L, Brock G, Sinclair I, Sullivan R, O'Neill V, Skog J, Flaherty K. 452 Profiling exosomal mRNAs in patients undergoing immunotherapy for malignant melanoma European Journal of Cancer. 51: S96. DOI: 10.1016/S0959-8049(16)30286-6 |
0.01 |
|
| 2015 |
Akbani R, Akdemir KC, Aksoy BA, Albert M, Ally A, Amin SB, Arachchi H, Arora A, Auman JT, Ayala B, Baboud J, Balasundaram M, Balu S, Barnabas N, Bartlett J, ... ... Flaherty KT, et al. Genomic Classification of Cutaneous Melanoma Cell. 161: 1681-1696. DOI: 10.1016/j.cell.2015.05.044 |
0.01 |
|
| 2015 |
Flaherty KT. Moving Forward: Making BRAF-Targeted Therapy Better Cancer Drug Discovery and Development. 82: 183-201. DOI: 10.1007/978-1-4939-2143-0_9 |
0.01 |
|
| 2015 |
Flaherty KT. New drugs in development for melanoma Clinical Advances in Hematology and Oncology. 13: 717-719. |
0.01 |
|
| 2014 |
Dummer R, Arenberger P, Ascierto PA, De Groot JW, Hallmeyer S, Lotem M, Long GV, Marples M, Schadendorf D, Starodub AN, Taylor M, Wolter P, Yamazaki N, Wasserman E, Ford J, ... ... Flaherty KT, et al. 1130TiPNEMO: A PHASE 3 TRIAL OF BINIMETINIB (MEK162) VERSUS DACARBAZINE IN PATIENTS WITH ADVANCED NRAS-MUTANT MELANOMA WHO ARE UNTREATED OR HAVE PROGRESSED AFTER ANY NUMBER OF IMMUNOTHERAPY REGIMENS. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 25: iv392. PMID 28171154 DOI: 10.1093/annonc/mdu344.46 |
0.01 |
|
| 2014 |
Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL, Rathmell JC, ... Flaherty KT, et al. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Science Signaling. 7: ra121. PMID 25538079 DOI: 10.1126/Scisignal.Aaa1877 |
0.01 |
|
| 2014 |
Wargo JA, Cooper ZA, Flaherty KT. Universes collide: Combining immunotherapy with targeted therapy for cancer Cancer Discovery. 4: 1377-1386. PMID 25395294 DOI: 10.1158/2159-8290.CD-14-0477 |
0.01 |
|
| 2014 |
Panka DJ, Buchbinder E, Giobbie-Hurder A, Schalck AP, Montaser-Kouhsari L, Sepehr A, Lawrence DP, McDermott DF, Cohen R, Carlson A, Wargo JA, Merritt R, Seery VJ, Hodi FS, Gunturi A, ... ... Flaherty KT, et al. Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma. Molecular Cancer Therapeutics. 13: 3210-8. PMID 25319388 DOI: 10.1158/1535-7163.MCT-14-0349 |
0.01 |
|
| 2014 |
Johnson DB, Flaherty KT, Weber JS, Infante JR, Kim KB, Kefford RF, Hamid O, Schuchter L, Cebon J, Sharfman WH, McWilliams RR, Sznol M, Lawrence DP, Gibney GT, Burris HA, et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 3697-704. PMID 25287827 DOI: 10.1200/JCO.2014.57.3535 |
0.01 |
|
| 2014 |
Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, ... ... Flaherty K, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. The New England Journal of Medicine. 371: 1877-88. PMID 25265492 DOI: 10.1056/NEJMoa1406037 |
0.01 |
|
| 2014 |
Smith MP, Sanchez-Laorden B, O'Brien K, Brunton H, Ferguson J, Young H, Dhomen N, Flaherty KT, Frederick DT, Cooper ZA, Wargo JA, Marais R, Wellbrock C. The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFα. Cancer Discovery. 4: 1214-29. PMID 25256614 DOI: 10.1158/2159-8290.CD-13-1007 |
0.01 |
|
| 2014 |
Romano D, Matallanas D, Frederick DT, Flaherty KT, Kolch W. One Hippo and many masters: differential regulation of the Hippo pathway in cancer. Biochemical Society Transactions. 42: 816-21. PMID 25109963 DOI: 10.1042/BST20140030 |
0.01 |
|
| 2014 |
Miller DM, Flaherty KT, Tsao H. Current status and future directions of molecularly targeted therapies and immunotherapies for melanoma. Seminars in Cutaneous Medicine and Surgery. 33: 60-7. PMID 25085663 DOI: 10.12788/j.sder.0081 |
0.01 |
|
| 2014 |
Frederick DT, Salas Fragomeni RA, Schalck A, Ferreiro-Neira I, Hoff T, Cooper ZA, Haq R, Panka DJ, Kwong LN, Davies MA, Cusack JC, Flaherty KT, Fisher DE, Mier JW, Wargo JA, et al. Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. Plos One. 9: e101286. PMID 24983357 DOI: 10.1371/Journal.Pone.0101286 |
0.01 |
|
| 2014 |
Haq R, Flaherty K. The melanoma metastasis X-factor. Pigment Cell & Melanoma Research. 27: 698. PMID 24953382 DOI: 10.1111/Pcmr.12285 |
0.01 |
|
| 2014 |
Cooper ZA, Juneja VR, Sage PT, Frederick DT, Piris A, Mitra D, Lo JA, Hodi FS, Freeman GJ, Bosenberg MW, McMahon M, Flaherty KT, Fisher DE, Sharpe AH, Wargo JA. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cancer Immunology Research. 2: 643-54. PMID 24903021 DOI: 10.1158/2326-6066.Cir-13-0215 |
0.01 |
|
| 2014 |
Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T, Zeng W, Giobbie-Hurder A, Atkins MB, Ibrahim N, Friedlander P, Flaherty KT, Murphy GF, Rodig S, Velazquez EF, et al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunology Research. 2: 632-42. PMID 24838938 DOI: 10.1158/2326-6066.CIR-14-0053 |
0.01 |
|
| 2014 |
Konieczkowski DJ, Johannessen CM, Abudayyeh O, Kim JW, Cooper ZA, Piris A, Frederick DT, Barzily-Rokni M, Straussman R, Haq R, Fisher DE, Mesirov JP, Hahn WC, Flaherty KT, Wargo JA, et al. A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors. Cancer Discovery. 4: 816-27. PMID 24771846 DOI: 10.1158/2159-8290.Cd-13-0424 |
0.01 |
|
| 2014 |
Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT, Sequist LV, McMahon M, Bosenberg MW, Stott SL, Ting DT, et al. Isolation and molecular characterization of circulating melanoma cells. Cell Reports. 7: 645-53. PMID 24746818 DOI: 10.1016/J.Celrep.2014.03.039 |
0.01 |
|
| 2014 |
Shtivelman E, Davies MQ, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE. Pathways and therapeutic targets in melanoma. Oncotarget. 5: 1701-52. PMID 24743024 DOI: 10.18632/Oncotarget.1892 |
0.01 |
|
| 2014 |
Sabbatino F, Wang Y, Wang X, Flaherty KT, Yu L, Pepin D, Scognamiglio G, Pepe S, Kirkwood JM, Cooper ZA, Frederick DT, Wargo JA, Ferrone S, Ferrone CR. PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget. 5: 1926-41. PMID 24732172 DOI: 10.18632/Oncotarget.1878 |
0.01 |
|
| 2014 |
Wilson MA, Zhao F, Letrero R, D'Andrea K, Rimm DL, Kirkwood JM, Kluger HM, Lee SJ, Schuchter LM, Flaherty KT, Nathanson KL. Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3328-37. PMID 24714776 DOI: 10.1158/1078-0432.Ccr-14-0093 |
0.01 |
|
| 2014 |
Padmanabhan RK, Somasundar VH, Griffith SD, Zhu J, Samoyedny D, Tan KS, Hu J, Liao X, Carin L, Yoon SS, Flaherty KT, Dipaola RS, Heitjan DF, Lal P, Feldman MD, et al. An active learning approach for rapid characterization of endothelial cells in human tumors. Plos One. 9: e90495. PMID 24603893 DOI: 10.1371/Journal.Pone.0090495 |
0.01 |
|
| 2014 |
Ackerman A, Klein O, McDermott DF, Wang W, Ibrahim N, Lawrence DP, Gunturi A, Flaherty KT, Hodi FS, Kefford R, Menzies AM, Atkins MB, Long GV, Sullivan RJ. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer. 120: 1695-701. PMID 24577748 DOI: 10.1002/cncr.28620 |
0.01 |
|
| 2014 |
Miller DM, Flaherty KT, Tsao H. Commentary: Molecular testing in melanoma. Journal of the American Academy of Dermatology. 70: 863-70. PMID 24534656 DOI: 10.1016/j.jaad.2014.01.866 |
0.01 |
|
| 2014 |
Balch CM, Thompson JF, Gershenwald JE, Soong SJ, Ding S, McMasters KM, Coit DG, Eggermont AMM, Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, Ross MI, Byrd DR, Cochran AJ, ... ... Flaherty KT, et al. Age as a predictor of sentinel node metastasis among patients with localized melanoma: An inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients Annals of Surgical Oncology. 21: 1075-1081. PMID 24531700 DOI: 10.1245/S10434-013-3464-X |
0.01 |
|
| 2014 |
Griewank KG, Scolyer RA, Thompson JF, Flaherty KT, Schadendorf D, Murali R. Genetic alterations and personalized medicine in melanoma: progress and future prospects. Journal of the National Cancer Institute. 106: djt435. PMID 24511108 DOI: 10.1093/jnci/djt435 |
0.01 |
|
| 2014 |
McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C, Testori A, Maio M, Lorigan P, Lebbé C, ... ... Flaherty KT, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. The Lancet. Oncology. 15: 323-32. PMID 24508103 DOI: 10.1016/S1470-2045(14)70012-9 |
0.01 |
|
| 2014 |
Flaherty KT, Hennig M, Lee SJ, Ascierto PA, Dummer R, Eggermont AM, Hauschild A, Kefford R, Kirkwood JM, Long GV, Lorigan P, Mackensen A, McArthur G, O'Day S, Patel PM, et al. Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. The Lancet. Oncology. 15: 297-304. PMID 24485879 DOI: 10.1016/S1470-2045(14)70007-5 |
0.01 |
|
| 2014 |
Flaherty L, Hamid O, Linette G, Schuchter L, Hallmeyer S, Gonzalez R, Cowey CL, Pavlick A, Kudrik F, Curti B, Lawson D, Chapman PB, Margolin K, Ribas A, McDermott D, ... Flaherty K, et al. A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States. Cancer Journal (Sudbury, Mass.). 20: 18-24. PMID 24445759 DOI: 10.1097/PPO.0000000000000024 |
0.01 |
|
| 2014 |
Sullivan RJ, Flaherty KT. Major therapeutic developments and current challenges in advanced melanoma British Journal of Dermatology. 170: 36-44. PMID 24443912 DOI: 10.1111/bjd.12698 |
0.01 |
|
| 2014 |
Miller DM, Flaherty KT. Cyclin-dependent kinases as therapeutic targets in melanoma. Pigment Cell & Melanoma Research. 27: 351-65. PMID 24405945 DOI: 10.1111/pcmr.12211 |
0.01 |
|
| 2014 |
Park JJ, Hawryluk EB, Tahan SR, Flaherty K, Kim CC. Cutaneous granulomatous eruption and successful response to potent topical steroids in patients undergoing targeted BRAF inhibitor treatment for metastatic melanoma. Jama Dermatology. 150: 307-11. PMID 24352115 DOI: 10.1001/jamadermatol.2013.7919 |
0.01 |
|
| 2014 |
Wagle N, Van Allen EM, Treacy DJ, Frederick DT, Cooper ZA, Taylor-Weiner A, Rosenberg M, Goetz EM, Sullivan RJ, Farlow DN, Friedrich DC, Anderka K, Perrin D, Johannessen CM, McKenna A, ... ... Flaherty KT, et al. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. Cancer Discovery. 4: 61-8. PMID 24265154 DOI: 10.1158/2159-8290.Cd-13-0631 |
0.01 |
|
| 2014 |
Ciunci CA, Perini RF, Avadhani AN, Kang HC, Sun W, Redlinger M, Harlacker K, Flaherty KT, Giantonio BJ, Rosen MA, Divgi CR, Song HK, Englander S, Troxel A, Schnall M, et al. Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer. Cancer. 120: 77-85. PMID 24108668 DOI: 10.1002/Cncr.28294 |
0.01 |
|
| 2014 |
Schultes BC, Chu CL, Long A, Sun E, Kurtagic E, Beccati D, Pradines J, Miller P, Ryan DP, Flaherty K, Roach J, Kaundinya GV. The effect and mechanism of M402 on gemcitabine uptake into pancreatic tumors. Journal of Clinical Oncology. 32: 215-215. DOI: 10.1200/jco.2014.32.3_suppl.215 |
0.01 |
|
| 2014 |
Ascierto PA, Flaherty K, Queirolo P, Sullivan RJ, Chiarion-Sileni V, Ridolfi R, Testori A, Simeone E, Grimaldi AM, Sabbatino F, Curvietto M, Ciliberto G, Botti G, Mozzillo N, Ferrone S. Phase I-II study of the combination vemurafenib plus peg-interferon in advanced melanoma patients harboring the V600BRAF mutation. Journal of Clinical Oncology. 32: TPS9105-TPS9105. DOI: 10.1200/Jco.2014.32.15_Suppl.Tps9105 |
0.01 |
|
| 2014 |
Flaherty K, Arenberger P, Ascierto PA, De Groot JW, Hallmeyer S, Long GV, Lotem M, Marples M, Schadendorf D, Starodub A, Taylor MH, Wolter P, Yamazaki N, Wasserman E, Ford J, et al. NEMO: A phase 3 trial of binimetinib (MEK162) versus dacarbazine in patients with untreated or progressed after first-line immunotherapy unresectable or metastatic NRAS-mutant cutaneous melanoma. Journal of Clinical Oncology. 32: TPS9102-TPS9102. DOI: 10.1200/JCO.2014.32.15_SUPPL.TPS9102 |
0.01 |
|
| 2014 |
Voss MH, Adamo B, Heist RS, Gandhi L, Moulon C, Tanaka H, Ishii N, Vaslin A, Aoki Y, Nicolas-Metral V, Brienza S, Zanna C, Flaherty K, Tabernero J, Baselga J. First-in-human phase I “basket” study of Debio1347 (CH5183284), a novel FGFR inhibitor, in patients with FGFR genomically activated advanced solid tumors. Journal of Clinical Oncology. 32: TPS2629-TPS2629. DOI: 10.1200/JCO.2014.32.15_SUPPL.TPS2629 |
0.01 |
|
| 2014 |
Zhao D, Sundaram S, Wakimoto H, Curry WT, Cahill DP, Batchelor T, Flaherty K, Allen J, Chi AS. ONC201, a small molecule Foxo3a activator, activity against patient-derived glioblastoma tumor-initiating cells. Journal of Clinical Oncology. 32: e13022-e13022. DOI: 10.1200/Jco.2014.32.15_Suppl.E13022 |
0.01 |
|
| 2014 |
Meier FE, Garbe C, Smalley K, Flaherty K, Schadendorf D, Beissert S, Kulms D, Niessner H. Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinib. Journal of Clinical Oncology. 32: 9062-9062. DOI: 10.1200/JCO.2014.32.15_SUPPL.9062 |
0.01 |
|
| 2014 |
Villaruz LC, Huang G, Romkes M, Kirkwood JM, Buch SC, Nukui T, Flaherty K, Lee SJ, Lee A, Pandit K, Abecassis I, Nathanson KL, Benos PV, Tawbi HA. microRNA (miRNA) expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy (CP) in metastatic melanoma (MM) treated on the intergroup trial E2603. Journal of Clinical Oncology. 32: 9048-9048. DOI: 10.1200/Jco.2014.32.15_Suppl.9048 |
0.01 |
|
| 2014 |
Long GV, Stroyakovsky DL, Gogas H, Levchenko E, de Braud F, Larkin JMG, Garbe C, Jouary T, Hauschild A, Grob JJ, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, DeMarini DJ, ... ... Flaherty K, et al. COMBI-d: A randomized, double-blinded, Phase III study comparing the combination of dabrafenib and trametinib to dabrafenib and trametinib placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAFV600E/K mutation-positive cutaneous melanoma Journal of Clinical Oncology. 32: 9011-9011. DOI: 10.1200/JCO.2014.32.15_SUPPL.9011 |
0.01 |
|
| 2014 |
Flaherty K, Daud A, Weber JS, Sosman JA, Kim K, Gonzalez R, Hamid O, Infante JR, Cebon JS, Schuchter LM, Long GV, Algazi AP, Kudchadkar RR, Puzanov I, Lawrence DP, et al. Updated overall survival (OS) for BRF113220, a phase 1-2 study of dabrafenib (D) alone versus combined dabrafenib and trametinib (D+T) in pts with BRAF V600 mutation-positive (+) metastatic melanoma (MM). Journal of Clinical Oncology. 32: 9010-9010. DOI: 10.1200/JCO.2014.32.15_SUPPL.9010 |
0.01 |
|
| 2014 |
Goldman JW, Gandhi L, Patnaik A, Rosen LS, Hilton JF, Papadopoulos KP, Tolaney SM, Beeram M, Rasco DW, Myrand SP, Beckmann RP, Kulanthaivel P, Frenzel M, Cronier D, Chan EM, ... Flaherty K, et al. Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer. Journal of Clinical Oncology. 32: 8026-8026. DOI: 10.1200/JCO.2014.32.15_SUPPL.8026 |
0.01 |
|
| 2014 |
Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Beeram M, Rasco DW, Myrand SP, Kulanthaivel P, Andrews JM, Frenzel M, Cronier D, Chan EM, ... Flaherty K, et al. LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer. Journal of Clinical Oncology. 32: 534-534. DOI: 10.1200/JCO.2014.32.15_SUPPL.534 |
0.01 |
|
| 2014 |
Vergote I, Ball DW, Kudo M, Sachdev P, Matijevic M, Kadowaki T, Funahashi Y, Flaherty K. Prognostic and predictive role of circulating angiopoietin-2 in multiple solid tumors: An analysis of approximately 500 patients treated with lenvatinib across tumor types. Journal of Clinical Oncology. 32: 11061-11061. DOI: 10.1200/JCO.2014.32.15_SUPPL.11061 |
0.01 |
|
| 2014 |
Kefford R, Sullivan RJ, Miller WH, Elez EM, Tan D, Kim KB, Long GV, Flaherty KT, Tai D, Stutvoet S, Maacke H, Whiley M, Parseval LM, Tabernero J. Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results Journal of Translational Medicine. 12: 5. DOI: 10.1186/1479-5876-12-S1-P5 |
0.01 |
|
| 2014 |
Wilson MA, Zhao F, Khare S, Letrero R, D'Andrea K, Rimm DL, Kirkwood JM, Kluger HM, Lee SJ, Schuchter LM, Flaherty KT, Nathanson KL. Abstract 933: Copy number changes are associated withBRAFandNRASmutations and response to treatment with carboplatin, paclitaxel and sorafenib Cancer Research. 74: 933-933. DOI: 10.1158/1538-7445.Am2014-933 |
0.01 |
|
| 2014 |
Luo X, Mitra D, Sullivan RJ, Wittner BS, Kimura AM, Pan S, Hoang MP, Brannigan BW, Lawrence DP, Flaherty KT, Sequist LV, Stott SL, Ting DT, Ramaswamy S, Toner M, et al. Abstract 4832: Isolation and molecular characterization of circulating melanoma cells Cancer Research. 74: 4832-4832. DOI: 10.1158/1538-7445.Am2014-4832 |
0.01 |
|
| 2014 |
Sabbatino F, Wang Y, Wang X, Flaherty KT, Pepin D, Scognamiglio G, Yu L, Cooper ZA, Pepe S, Kirkwood JM, Frederick DT, Wargo JA, Ferrone S, Ferrone CR. Abstract 3703: PDGFRα up-regulation mediated by Sonic Hedgehog Pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation Cancer Research. 74: 3703-3703. DOI: 10.1158/1538-7445.Am2014-3703 |
0.01 |
|
| 2014 |
Paraiso KHT, Thakur MD, John JK, Fang B, Koomen JM, Fedorenko IV, Tsao H, Flaherty KT, Messina JL, Pasquale EM, Villagra A, Kirkwood JM, Meier F, Sloot S, Gibney GT, et al. Abstract 1610: MAPK inhibitor resistance leads to ligand-independent Ephrin A2 receptor signaling and the formation of new melanoma metastases Cancer Research. 74: 1610-1610. DOI: 10.1158/1538-7445.Am2014-1610 |
0.01 |
|
| 2014 |
Krepler C, Sproesser K, Brafford P, Xiao M, Beqiri M, Xu W, Nathanson K, Wargo J, Flaherty K, Morton DL, Hoon DS, Ryan R, Guarino M, Petrelli NJ, Elder D, et al. Abstract 1182: Patient derived xenograft (PDX) of human melanoma to predict clinical responses Cancer Research. 74: 1182-1182. DOI: 10.1158/1538-7445.Am2014-1182 |
0.01 |
|
| 2014 |
Griewank KG, Scolyer RA, Thompson JF, Flaherty KT, Schadendorf D, Murali R. Genetic alterations and personalized medicine in melanoma: Progress and future prospects Journal of the National Cancer Institute. 106. DOI: 10.1093/jnci/djt435 |
0.01 |
|
| 2014 |
Kwak E, Juric D, Cleary J, Cote G, Hilton J, Flaherty K, Wood K, Rance C, Barrett S, Shapiro G. 484 Treatment of advanced solid tumors with golvatinib (E7050) in combination with lenvatinib (E7080) European Journal of Cancer. 50: 158. DOI: 10.1016/S0959-8049(14)70610-0 |
0.01 |
|
| 2014 |
Enderle D, Brinkmann K, Koestler T, Bentink S, Flaherty K, Skog J, Noerholm M. 454 Monitoring therapy response and resistance mutations in circulating RNA and DNA of plasma from patients with malignant melanoma European Journal of Cancer. 50: 149. DOI: 10.1016/S0959-8049(14)70580-5 |
0.01 |
|
| 2014 |
Schalck A, Frederick D, Hammond M, Ferreiro-Neira I, Cooper Z, Cusack J, Lawrence D, Flaherty K, Wargo J, Sullivan R. 314 Optimal sequencing schedules for combining BRAF inhibition with BCL-2 inhibition European Journal of Cancer. 50: 102. DOI: 10.1016/S0959-8049(14)70440-X |
0.01 |
|
| 2014 |
Shtivelman E, Davies MA, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE. Pathways and therapeutic targets in melanoma Oncotarget. 5: 1701-1752. |
0.01 |
|
| 2014 |
Sabbatino F, Wang Y, Wang X, Flaherty KT, Yu L, Pepin D, Scognamiglio G, Pepe S, Kirkwood JM, Cooper ZA, Frederick DT, Wargo JA, Ferrone S, Ferrone CR. PDGFRa up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation Oncotarget. 5: 1926-1941. |
0.01 |
|
| 2013 |
Juric D, Isakoff SJ, Borger DR, Dias-Santagata D, Higgins MJ, Iafrate AJ, Flaherty K, Moy B, Ellisen LW. Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 145. PMID 28136532 DOI: 10.1200/Jco.2013.31.15_Suppl.533 |
0.01 |
|
| 2013 |
Cooper ZA, Frederick DT, Juneja VR, Sullivan RJ, Lawrence DP, Piris A, Sharpe AH, Fisher DE, Flaherty KT, Wargo JA. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology. 2: e26615. PMID 24251082 DOI: 10.4161/Onci.26615 |
0.01 |
|
| 2013 |
Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, Narayan R, Flaherty KT, Wargo JA, Root DE, Garraway LA. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature. 504: 138-42. PMID 24185007 DOI: 10.1038/Nature12688 |
0.01 |
|
| 2013 |
Niessner H, Forschner A, Klumpp B, Honegger JB, Witte M, Bornemann A, Dummer R, Adam A, Bauer J, Tabatabai G, Flaherty K, Sinnberg T, Beck D, Leiter U, Mauch C, et al. Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Medicine. 2: 76-85. PMID 24133630 DOI: 10.1002/cam4.50 |
0.01 |
|
| 2013 |
O'Connell MP, Marchbank K, Webster MR, Valiga AA, Kaur A, Vultur A, Li L, Herlyn M, Villanueva J, Liu Q, Yin X, Widura S, Nelson J, Ruiz N, Camilli TC, ... ... Flaherty KT, et al. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discovery. 3: 1378-93. PMID 24104062 DOI: 10.1158/2159-8290.Cd-13-0005 |
0.01 |
|
| 2013 |
Sullivan RJ, LoRusso PM, Flaherty KT. The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: Where we have been, are, and will be Clinical Cancer Research. 19: 5283-5291. PMID 24089441 DOI: 10.1158/1078-0432.CCR-13-2151 |
0.01 |
|
| 2013 |
Fridlyand J, Simon RM, Walrath JC, Roach N, Buller R, Schenkein DP, Flaherty KT, Allen JD, Sigal EV, Scher HI. Considerations for the successful co-development of targeted cancer therapies and companion diagnostics. Nature Reviews. Drug Discovery. 12: 743-55. PMID 24008432 DOI: 10.1038/nrd4101 |
0.01 |
|
| 2013 |
Jilaveanu LB, Zhao F, Zito CR, Kirkwood JM, Nathanson KL, D'Andrea K, Wilson M, Rimm DL, Flaherty KT, Lee SJ, Kluger HM. Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel. Plos One. 8: e69748. PMID 23936348 DOI: 10.1371/Journal.Pone.0069748 |
0.01 |
|
| 2013 |
Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D'Angelo S, Dickson M, et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 119: 3687-95. PMID 23913718 DOI: 10.1002/Cncr.28282 |
0.01 |
|
| 2013 |
Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, et al. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Science Translational Medicine. 5: 196ra98. PMID 23903755 DOI: 10.1126/Scitranslmed.3005753 |
0.01 |
|
| 2013 |
Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Coit DG, Atkins MB, Ding S, Cochran AJ, Eggermont AMM, Flaherty KT, Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, McMasters KM, et al. Age as a prognostic factor in patients with localized melanoma and regional metastases Annals of Surgical Oncology. 20: 3961-3968. PMID 23838920 DOI: 10.1245/S10434-013-3100-9 |
0.01 |
|
| 2013 |
Ji Z, Kumar R, Taylor M, Rajadurai A, Marzuka-Alcalá A, Chen YE, Njauw CN, Flaherty K, Jönsson G, Tsao H. Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4383-91. PMID 23812671 DOI: 10.1158/1078-0432.CCR-13-0074 |
0.01 |
|
| 2013 |
Hodi FS, Corless CL, Giobbie-Hurder A, Fletcher JA, Zhu M, Marino-Enriquez A, Friedlander P, Gonzalez R, Weber JS, Gajewski TF, O'Day SJ, Kim KB, Lawrence D, Flaherty KT, Luke JJ, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 3182-90. PMID 23775962 DOI: 10.1200/JCO.2012.47.7836 |
0.01 |
|
| 2013 |
Salama AKS, Flaherty KT. BRAF in melanoma: Current strategies and future directions Clinical Cancer Research. 19: 4326-4334. PMID 23770823 DOI: 10.1158/1078-0432.CCR-13-0779 |
0.01 |
|
| 2013 |
Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, Callahan MK, Harding JJ, D'Angelo SP, Dickson MA, Schwartz GK, et al. Ipilimumab for patients with advanced mucosal melanoma. The Oncologist. 18: 726-32. PMID 23716015 DOI: 10.1634/Theoncologist.2012-0464 |
0.01 |
|
| 2013 |
Bennett A, Bukowski RM, Flaherty K, Muir JC, Turner CD, Donaldson S. The Cost of Hope: a candid roundtable discussion. Journal of the National Comprehensive Cancer Network : Jnccn. 11: 633-5. PMID 23704231 DOI: 10.6004/JNCCN.2013.0189 |
0.01 |
|
| 2013 |
Salas Fragomeni RA, Chung HW, Landesman Y, Senapedis W, Saint-Martin JR, Tsao H, Flaherty KT, Shacham S, Kauffman M, Cusack JC. CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma. Molecular Cancer Therapeutics. 12: 1171-9. PMID 23615632 DOI: 10.1158/1535-7163.MCT-12-1171 |
0.01 |
|
| 2013 |
Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 1767-74. PMID 23569304 DOI: 10.1200/JCO.2012.44.7888 |
0.01 |
|
| 2013 |
Merlino G, Flaherty K, Acquavella N, Day CP, Aplin A, Holmen S, Topalian S, Van Dyke T, Herlyn M. Meeting report: The future of preclinical mouse models in melanoma treatment is now. Pigment Cell & Melanoma Research. 26: E8-E14. PMID 23531109 DOI: 10.1111/Pcmr.12099 |
0.01 |
|
| 2013 |
Desai BM, Villanueva J, Nguyen TT, Lioni M, Xiao M, Kong J, Krepler C, Vultur A, Flaherty KT, Nathanson KL, Smalley KS, Herlyn M. The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. Plos One. 8: e59588. PMID 23527225 DOI: 10.1371/Journal.Pone.0059588 |
0.01 |
|
| 2013 |
Beck D, Niessner H, Smalley KS, Flaherty K, Paraiso KH, Busch C, Sinnberg T, Vasseur S, Iovanna JL, Drießen S, Stork B, Wesselborg S, Schaller M, Biedermann T, Bauer J, et al. Vemurafenib potently induces endoplasmic reticulum stress-mediated apoptosis in BRAFV600E melanoma cells. Science Signaling. 6: ra7. PMID 23362240 DOI: 10.1126/scisignal.2003057 |
0.01 |
|
| 2013 |
Hollebecque A, Postel-Vinay S, Verweij J, Demetri GD, Flaherty K, Bedard P, Soria JC. Modifying phase I methodology to facilitate enrolment of molecularly selected patients. European Journal of Cancer (Oxford, England : 1990). 49: 1515-20. PMID 23333057 DOI: 10.1016/j.ejca.2012.12.012 |
0.01 |
|
| 2013 |
Frederick DT, Piris A, Cogdill AP, Cooper ZA, Lezcano C, Ferrone CR, Mitra D, Boni A, Newton LP, Liu C, Peng W, Sullivan RJ, Lawrence DP, Hodi FS, Overwijk WW, ... ... Flaherty KT, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 1225-31. PMID 23307859 DOI: 10.1158/1078-0432.Ccr-12-1630 |
0.01 |
|
| 2013 |
Sullivan RJ, Flaherty KT. Resistance to BRAF-targeted therapy in melanoma European Journal of Cancer. 49: 1297-1304. PMID 23290787 DOI: 10.1016/j.ejca.2012.11.019 |
0.01 |
|
| 2013 |
Kang HC, Tan KS, Keefe SM, Heitjan DF, Siegelman ES, Flaherty KT, O'Dwyer PJ, Rosen MA. MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib. Ajr. American Journal of Roentgenology. 200: 120-6. PMID 23255750 DOI: 10.2214/Ajr.12.8536 |
0.01 |
|
| 2013 |
Flaherty KT, Lee SJ, Zhao F, Schuchter LM, Flaherty L, Kefford R, Atkins MB, Leming P, Kirkwood JM. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 373-9. PMID 23248256 DOI: 10.1200/JCO.2012.42.1529 |
0.01 |
|
| 2013 |
Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, ... Flaherty KT, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 181-6. PMID 23213094 DOI: 10.1200/Jco.2012.43.3383 |
0.01 |
|
| 2013 |
Liu C, Peng W, Xu C, Lou Y, Zhang M, Wargo JA, Chen JQ, Li HS, Watowich SS, Yang Y, Tompers Frederick D, Cooper ZA, Mbofung RM, Whittington M, Flaherty KT, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 393-403. PMID 23204132 DOI: 10.1158/1078-0432.Ccr-12-1626 |
0.01 |
|
| 2013 |
Nardi V, Sadow PM, Juric D, Zhao D, Cosper AK, Bergethon K, Scialabba VL, Batten JM, Borger DR, Iafrate AJ, Heist RS, Lawrence DP, Flaherty KT, Bendell JC, Deschler D, et al. Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 480-90. PMID 23186780 DOI: 10.1158/1078-0432.Ccr-12-1842 |
0.01 |
|
| 2013 |
Maertens O, Johnson B, Hollstein P, Frederick DT, Cooper ZA, Messiaen L, Bronson RT, McMahon M, Granter S, Flaherty K, Wargo JA, Marais R, Cichowski K. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discovery. 3: 338-49. PMID 23171796 DOI: 10.1158/2159-8290.Cd-12-0313 |
0.01 |
|
| 2013 |
Mattei PL, Alora-Palli MB, Kraft S, Lawrence DP, Flaherty KT, Kimball AB. Cutaneous effects of BRAF inhibitor therapy: a case series. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 530-7. PMID 23035153 DOI: 10.1093/annonc/mds292 |
0.01 |
|
| 2013 |
Shah A, Motiwala S, O'Dwyer PJ, Flaherty KT, Keefe SM. Increase in blood pressure with sorafenib exposure in renal cell carcinoma versus other solid tumors. Journal of Clinical Oncology. 31: 384-384. DOI: 10.1200/jco.2013.31.6_suppl.384 |
0.01 |
|
| 2013 |
McDermott DF, Manola J, Pins M, Flaherty KT, Atkins MB, Dutcher JP, George DJ, Margolin KA, DiPaola RS. The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC). Journal of Clinical Oncology. 31: 345-345. DOI: 10.1200/jco.2013.31.6_suppl.345 |
0.01 |
|
| 2013 |
Bardia A, Juric D, Isakoff SJ, Borger DR, Dias-Santagata D, Higgins MJ, Iafrate AJ, Flaherty K, Moy B, Ellisen LW. Impact of routine tumor genotyping on enrollment in targeted therapy trials for metastatic breast cancer (MBC): 4-year review. Journal of Clinical Oncology. 31: 145-145. DOI: 10.1200/jco.2013.31.26_suppl.145 |
0.01 |
|
| 2013 |
Meier FE, Niessner H, Schmitz J, Schmid A, Calaminus C, Pichler B, Forschner A, Flaherty K, Honegger JB, Dummer R, Tabatabai G, Weide B, Eigentler TK, Schadendorf D, Quintanilla-Fend L, et al. The PI3K inhibitor BKM120 has potent antitumor activity in melanoma brain metastases in vitro and in vivo. Journal of Clinical Oncology. 31: e20050-e20050. DOI: 10.1200/JCO.2013.31.15_SUPPL.E20050 |
0.01 |
|
| 2013 |
Love N, Anderson KC, Flaherty K, Kantarjian HM, Lynch TJ, O'Shaughnessy J, Sartor AO, Venook AP, Zelenetz AD, Moss J, Kelly G, Ziel K. Medical oncologists’ clinical experiences and comfort levels with 20 recently approved agents. Journal of Clinical Oncology. 31: e17570-e17570. DOI: 10.1200/JCO.2013.31.15_SUPPL.E17570 |
0.01 |
|
| 2013 |
Shah A, Motiwala S, Brose MS, O'Dwyer PJ, Flaherty K, Keefe SM. Increase in blood pressure with sorafenib exposure: Renal cell carcinoma (RCC) versus other solid tumors. Journal of Clinical Oncology. 31: e15564-e15564. DOI: 10.1200/JCO.2013.31.15_SUPPL.E15564 |
0.01 |
|
| 2013 |
Daud A, Kluger HM, Edelman G, Gordon MS, Schimmoller F, Weitzman A, Samuel TA, Moussa AH, Flaherty K, Shapiro G. Activity of cabozantinib in metastatic uveal melanoma: Updated results from a phase II randomized discontinuation trial (RDT). Journal of Clinical Oncology. 31: 9094-9094. DOI: 10.1200/JCO.2013.31.15_SUPPL.9094 |
0.01 |
|
| 2013 |
Sullivan RJ, Ibrahim N, Lawrence DP, Aldridge J, Hodi FS, Flaherty K, Conley C, DeNoble S, Mier JW, Cho DC, Atkins MB, McDermott DF. A phase I study of the combination of sorafenib (Sor) and bortezomib (Bor) in patients (pts) with metastatic melanoma (MM). Journal of Clinical Oncology. 31: 9076-9076. DOI: 10.1200/jco.2013.31.15_suppl.9076 |
0.01 |
|
| 2013 |
Schuchter LM, Kudchadkar RR, Gonzalez R, Lawrence DP, Sosman JA, Infante JR, Daud A, Kefford R, Cebon JS, Sharfman WH, Amaravadi RK, Boasberg PD, Lewis KD, Flaherty K, Ouellet D, et al. Efficacy, safety, and pharmacokinetics (PK) of the BRAF inhibitor dabrafenib (D) hydroxypropyl methylcellulose (HPMC) capsule formulation in combination with the MEK1/2 inhibitor trametinib (T) in patients (pts) with BRAF mutation-positive metastatic melanoma (MM). Journal of Clinical Oncology. 31: 9066-9066. DOI: 10.1200/JCO.2013.31.15_SUPPL.9066 |
0.01 |
|
| 2013 |
Wattson DA, Shih HA, Niemierko A, Merritt RM, Lawrence DP, Oh KS, Sullivan RJ, Flaherty K. Survival patterns following brain metastases for patients with melanoma in the targeted therapy era. Journal of Clinical Oncology. 31: 9064-9064. DOI: 10.1200/JCO.2013.31.15_SUPPL.9064 |
0.01 |
|
| 2013 |
Sachdev P, Hamid O, Kim K, Hauschild A, O'Day S, Andresen C, Funahashi Y, Kadowaki T, O'Brien JP, Flaherty K. Analysis of serum biomarkers and tumor genetic alterations from a phase II study of lenvatinib in patients with advanced BRAF wild-type melanoma. Journal of Clinical Oncology. 31: 9058-9058. DOI: 10.1200/JCO.2013.31.15_SUPPL.9058 |
0.01 |
|
| 2013 |
Kefford R, Miller WH, Tan DS, Sullivan RJ, Long G, Dienstmann R, Tai WMD, Flaherty K, Stutvoet S, Schumacher KM, Wandel S, Parseval LAD, Tabernero J. Preliminary results from a phase Ib/II, open-label, dose-escalation study of the oral BRAF inhibitor LGX818 in combination with the oral MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors. Journal of Clinical Oncology. 31: 9029-9029. DOI: 10.1200/Jco.2013.31.15_Suppl.9029 |
0.01 |
|
| 2013 |
Dummer R, Robert C, Nyakas M, McArthur GA, Kudchadkar RR, Gomez-Roca C, Sullivan RJ, Flaherty K, Murer C, Michel D, Tang Z, De Parseval LA, Delord J. Initial results from a phase I, open-label, dose escalation study of the oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or metastatic melanoma. Journal of Clinical Oncology. 31: 9028-9028. DOI: 10.1200/JCO.2013.31.15_SUPPL.9028 |
0.01 |
|
| 2013 |
O'Day S, Gonzalez R, Kim K, Chmielowski B, Kefford R, Long G, Loquai C, Cowey CL, Hauschild A, Hainsworth JD, Hersey P, Boyle F, Evans TRJ, Hamid O, Meneses N, ... ... Flaherty K, et al. A phase II study of the multitargeted kinase inhibitor lenvatinib in patients with advanced BRAF wild-type melanoma. Journal of Clinical Oncology. 31: 9026-9026. DOI: 10.1200/JCO.2013.31.15_SUPPL.9026 |
0.01 |
|
| 2013 |
Schadendorf D, Flaherty K, Hersey P, Nathan PD, Garbe C, Milhem MM, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JMG, Utikal J, Casey M, et al. Tumor-specific circulating cell-free DNA (cfDNA) to predict clinical outcome in BRAF V600 mutation-positive melanoma patients (pts) treated with the MEK inhibitor trametinib (T) or chemotherapy (C). Journal of Clinical Oncology. 31: 9020-9020. DOI: 10.1200/JCO.2013.31.15_SUPPL.9020 |
0.01 |
|
| 2013 |
Cebon JS, Flaherty K, Weber JS, Kim K, Infante JR, Daud A, Hamid O, Kefford R, Schuchter LM, Sosman JA, Sznol M, Sharfman WH, Gonzalez R, Andrews MC, Dronca RS, et al. Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib (T). Journal of Clinical Oncology. 31: 9016-9016. DOI: 10.1200/JCO.2013.31.15_SUPPL.9016 |
0.01 |
|
| 2013 |
Wagle N, Allen EMV, Frederick DT, Cooper ZA, Farlow DN, Treacy D, Goetz EM, Johannessen CM, Carter SL, Taylor-Weiner A, Hodis E, Lawrence DP, Sullivan RJ, Getz G, Gabriel SB, ... Flaherty K, et al. Whole exome and whole transcriptome sequencing in melanoma patients to identify mechanisms of resistance to combined RAF/MEK inhibition. Journal of Clinical Oncology. 31: 9015-9015. DOI: 10.1200/Jco.2013.31.15_Suppl.9015 |
0.01 |
|
| 2013 |
Hamid O, Sosman JA, Lawrence DP, Sullivan RJ, Ibrahim N, Kluger HM, Boasberg PD, Flaherty K, Hwu P, Ballinger M, Mokatrin A, Kowanetz M, Chen DS, Hodi FS. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM). Journal of Clinical Oncology. 31: 9010-9010. DOI: 10.1200/Jco.2013.31.15_Suppl.9010 |
0.01 |
|
| 2013 |
Sosman JA, Daud A, Weber JS, Kim K, Kefford R, Flaherty K, Infante JR, Hamid O, Cebon JS, Schuchter LM, McWilliams RR, Sznol M, Sharfman WH, Algazi AP, Lewis KD, et al. BRAF inhibitor (BRAFi) dabrafenib in combination with the MEK1/2 inhibitor (MEKi) trametinib in BRAFi-naive and BRAFi-resistant patients (pts) with BRAF mutation-positive metastatic melanoma (MM). Journal of Clinical Oncology. 31: 9005-9005. DOI: 10.1200/JCO.2013.31.15_SUPPL.9005 |
0.01 |
|
| 2013 |
Shapiro G, Rosen LS, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, Tolaney SM, Beeram M, Rasco DW, Kulanthaivel P, Li Q, Hu T, Cronier D, Chan EM, Flaherty K, et al. A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer. Journal of Clinical Oncology. 31: 2500-2500. DOI: 10.1200/jco.2013.31.15_suppl.2500 |
0.01 |
|
| 2013 |
Paraiso KHT, Fang B, Han D, Fedorenko I, John J, Koomen J, Wargo J, Flaherty K, Meier F, Smalley KSM. Abstract 5237: Systems level modeling following BRAF inhibition reveals an essential role for Ephrin A2 receptor in therapeutic escape. Cancer Research. 73: 5237-5237. DOI: 10.1158/1538-7445.Am2013-5237 |
0.01 |
|
| 2013 |
Maertens O, Johnson B, Hollstein P, Frederick D, Cooper Z, Messiaen L, Bronson R, McMahon M, Granter S, Flaherty K, Wargo J, Marais R, Cichowski K. Abstract 5201: Elucidating distinct roles for NF1 in melanomagenesis. Cancer Research. 73: 5201-5201. DOI: 10.1158/1538-7445.Am2013-5201 |
0.01 |
|
| 2013 |
Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Winokur D, Piris A, Nazarian RM, Brown RD, Godfrey JT, Mino-Kenudson M, Settleman J, Wargo JA, Flaherty KT, Haber DA, Engelman JA. Abstract 4568: Rapid assessment of TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF mutant melanoma. Cancer Research. 73: 4568-4568. DOI: 10.1158/1538-7445.Am2013-4568 |
0.01 |
|
| 2013 |
Corcoran RB, Rothenberg SM, Hata AN, Faber AC, Piris A, Nazarian RM, Brown RD, Godfrey JT, Winokur D, Walsh J, Mino-Kenudson M, Maheswaran S, Settleman J, Wargo JA, Flaherty KT, et al. Abstract C137: Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C137 |
0.01 |
|
| 2013 |
Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Flaherty KT, Wargo JA, Root DE, Garraway LA. Abstract PR10: A cyclic AMP-regulated melanocyte lineage program confers resistance to MAP kinase pathway inhibition Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Pms-Pr10 |
0.01 |
|
| 2013 |
Salas Fragomeni RA, Chung HW, Landesman Y, Senapedis W, Saint-Martin JR, Tsao H, Flaherty KT, Shacham S, Kauffman M, Cusack JC. CRM1 and BRAF inhibition synergize and induce tumor regression in BRAF-mutant melanoma Molecular Cancer Therapeutics. 12: 1171-1179. DOI: 10.1158/1535-7163.MCT-12-1171 |
0.01 |
|
| 2013 |
Friedman AA, Flaherty KT. Scratching the combinatorial drug landscape surface Pigment Cell and Melanoma Research. 26: 297-299. DOI: 10.1111/Pcmr.12072 |
0.01 |
|
| 2013 |
Corcoran R, Rothenberg M, Piris A, Nazarian R, Maheswaran S, Settleman J, Wargo J, Flaherty K, Haber D, Engelman J. MC13-0075 Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients European Journal of Cancer. 49: S12. DOI: 10.1016/S0959-8049(13)70119-9 |
0.01 |
|
| 2012 |
Flaherty KT, Hersey P, Nathan PD, Garbe C, Milhem MM, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Casey M, Sherman LJ, et al. METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAFV600E/K mutant advanced or metastatic melanoma (MM). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: LBA8509. PMID 28140819 DOI: 10.1200/jco.2012.30.18_suppl.lba8509 |
0.01 |
|
| 2012 |
Belden S, Flaherty KT. MEK and RAF inhibitors for BRAF-mutated cancers Expert Reviews in Molecular Medicine. 14. PMID 23058743 |
0.01 |
|
| 2012 |
Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA, Falchook G, Algazi A, Lewis K, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. The New England Journal of Medicine. 367: 1694-703. PMID 23020132 DOI: 10.1056/NEJMoa1210093 |
0.01 |
|
| 2012 |
Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, Jakubosky D, Genovese G, Muller FL, Jeong JH, Bender RP, Chu GC, Flaherty KT, Wargo JA, Collins JJ, et al. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nature Medicine. 18: 1503-10. PMID 22983396 DOI: 10.1038/Nm.2941 |
0.01 |
|
| Hide low-probability matches. |